<html lang="en" class="pb-page js" data-request-id="94d63046808d1cd3-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d63046808d1cd3-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/iqhd8tC0v9mKFnOsvHZkdffwzisndf3LyQOi_xv0Ce9AdqTYz0Ljsze9U1hf2Qk8pPjtDME1BHPQ1r3KC7Lgqw=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d63046808d1cd3-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.8862190855503984"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="topics" content="Childhood Cancer|Treatments in Oncology|Leukemia/Lymphoma">
<meta name="articleCategory" content="Research">
<meta name="articleType" content="Original Article">
<meta name="Specialties" content="Hematology/Oncology"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa1915315","title":"Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children","category":"Research","type":"Original Article","topics":"Childhood Cancer|Treatments in Oncology|Leukemia/Lymphoma","specialties":"Hematology/Oncology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-06-04T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"topics\" content\u003d\"Childhood Cancer|Treatments in Oncology|Leukemia/Lymphoma\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Hematology/Oncology\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa1915315","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d63046808d1cd3-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children"><meta name="dc.Creator" content="Véronique Minard-Colin"><meta name="dc.Creator" content="Anne Aupérin"><meta name="dc.Creator" content="Marta Pillon"><meta name="dc.Creator" content="G.A. Amos Burke"><meta name="dc.Creator" content="Donald A. Barkauskas"><meta name="dc.Creator" content="Keith Wheatley"><meta name="dc.Creator" content="Rafael F. Delgado"><meta name="dc.Creator" content="Sarah Alexander"><meta name="dc.Creator" content="Anne Uyttebroeck"><meta name="dc.Creator" content="Catherine M. Bollard"><meta name="dc.Creator" content="József Zsiros"><meta name="dc.Creator" content="Monika Csoka"><meta name="dc.Creator" content="Bernarda Kazanowska"><meta name="dc.Creator" content="Alan K. Chiang"><meta name="dc.Creator" content="Rodney R. Miles"><meta name="dc.Creator" content="Andrew Wotherspoon"><meta name="dc.Creator" content="Peter C. Adamson"><meta name="dc.Creator" content="Gilles Vassal"><meta name="dc.Creator" content="Catherine Patte"><meta name="dc.Creator" content="Thomas G. Gross"><meta name="dc.Description" content="Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin’s lymphoma are limited.We c..."><meta name="Description" content="Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin’s lymphoma are limited.We c..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2020-06-04"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa1915315"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202006043822310"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="YXQYoa1915315"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa1915315">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa1915315">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa1915315">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children | NEJM">
        <meta property="og:title" content="Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa1915315">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/2b0f3dff-a893-4615-a023-46366d995877/nejmoa1915315_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/2b0f3dff-a893-4615-a023-46366d995877/nejmoa1915315_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer.
Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin’s
lymphoma are limited. We ...">
        <meta name="twitter:description" content="Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer.
Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin’s
lymphoma are limited. We ...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="2895">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa1915315">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1915315">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:MMS NextGen Website Group;article:article:doi\:10.1056/NEJMoa1915315;issue:issue:doi\:10.1056/nejm_2020.382.issue-23;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1915315" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1915315" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1915315" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa1915315" class="inputDoi"><input type="hidden" value="V. Minard-Colin and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;382:2207-2219" class="inputCitation"><input type="hidden" value="06-03-2020" class="inputEPubDate"><input type="hidden" value="June 2020" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d63046808d1cd3-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li><div style="clear: both;"></div></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Véronique</span> <span property="familyName">Minard-Colin</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-0296-5207" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-0296-5207</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anne</span> <span property="familyName">Aupérin</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Marta</span> <span property="familyName">Pillon</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">G.A. Amos</span> <span property="familyName">Burke</span>, <span property="honorificSuffix">M.B., Ch.B., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Donald A.</span> <span property="familyName">Barkauskas</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Keith</span> <span property="familyName">Wheatley</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Rafael F.</span> <span property="familyName">Delgado</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+14</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sarah</span> <span property="familyName">Alexander</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Anne</span> <span property="familyName">Uyttebroeck</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Catherine M.</span> <span property="familyName">Bollard</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">József</span> <span property="familyName">Zsiros</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Monika</span> <span property="familyName">Csoka</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Bernarda</span> <span property="familyName">Kazanowska</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Alan K.</span> <span property="familyName">Chiang</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-1089-5325" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-1089-5325</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Rodney R.</span> <span property="familyName">Miles</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Andrew</span> <span property="familyName">Wotherspoon</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Peter C.</span> <span property="familyName">Adamson</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Gilles</span> <span property="familyName">Vassal</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Catherine</span> <span property="familyName">Patte</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Thomas G.</span> <span property="familyName">Gross</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, for <span property="author" typeof="Person" role="listitem">the European Intergroup for Childhood Non-Hodgkin Lymphoma</span></span>, for <span property="author" typeof="Person" role="listitem">the Children’s Oncology Group<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-14</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">June 3, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">382</span></span>:<span property="pageStart">2207</span>-<span property="pageEnd">2219</span></div><div class="doi">DOI: 10.1056/NEJMoa1915315</div><div class="core-enumeration"><a href="/toc/nejm/382/23"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">382</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">23</span></span></a></div><div><a href="#tab-information">Copyright © 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DV%25C3%25A9ronique%2BMinard-Colin%252C%2BAnne%2BAup%25C3%25A9rin%252C%2BMarta%2BPillon%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D382%26issueNum%3D23%26contentID%3D10.1056%252FNEJMoa1915315%26title%3DRituximab%2Bfor%2BHigh-Risk%252C%2BMature%2BB-Cell%2BNon-Hodgkin%25E2%2580%2599s%2BLymphoma%2Bin%2BChildren%26publicationDate%3D06%252F04%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa1915315" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DV%25C3%25A9ronique%2BMinard-Colin%252C%2BAnne%2BAup%25C3%25A9rin%252C%2BMarta%2BPillon%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D382%26issueNum%3D23%26contentID%3D10.1056%252FNEJMoa1915315%26title%3DRituximab%2Bfor%2BHigh-Risk%252C%2BMature%2BB-Cell%2BNon-Hodgkin%25E2%2580%2599s%2BLymphoma%2Bin%2BChildren%26publicationDate%3D06%252F04%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/af5b5a04-7d87-47d4-ae30-98f35e9648d3/nejmoa1915315.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa1915315.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1915315" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1915315" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1915315.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin’s lymphoma are limited.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted an open-label, international, randomized, phase 3 trial involving patients younger than 18 years of age with high-risk, mature B-cell non-Hodgkin’s lymphoma (stage III with an elevated lactate dehydrogenase level or stage IV) or acute leukemia to compare the addition of six doses of rituximab to standard lymphomes malins B (LMB) chemotherapy with standard LMB chemotherapy alone. The primary end point was event-free survival. Overall survival and toxic effects were also assessed.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">Analyses were based on 328 patients who underwent randomization (164 patients per group); 85.7% of the patients had Burkitt’s lymphoma. The median follow-up was 39.9 months. Events were observed in 10 patients in the rituximab–chemotherapy group and in 28 in the chemotherapy group. Event-free survival at 3 years was 93.9% (95% confidence interval [CI], 89.1 to 96.7) in the rituximab–chemotherapy group and 82.3% (95% CI, 75.7 to 87.5) in the chemotherapy group (hazard ratio for primary refractory disease or first occurrence of progression, relapse after response, death from any cause, or second cancer, 0.32; 95% CI, 0.15 to 0.66; one-sided P=0.00096, which reached the significance level required for this analysis). Eight patients in the rituximab–chemotherapy group died (4 deaths were disease-related, 3 were treatment-related, and 1 was from a second cancer), as did 20 in the chemotherapy group (17 deaths were disease-related, and 3 were treatment-related) (hazard ratio, 0.36; 95% CI, 0.16 to 0.82). The incidence of acute adverse events of grade 4 or higher after prephase treatment was 33.3% in the rituximab–chemotherapy group and 24.2% in the chemotherapy group (P=0.07); events were related mainly to febrile neutropenia and infection. Approximately twice as many patients in the rituximab–chemotherapy group as in the chemotherapy group had a low IgG level 1 year after trial inclusion.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Rituximab added to standard LMB chemotherapy markedly prolonged event-free survival and overall survival among children and adolescents with high-grade, high-risk, mature B-cell non-Hodgkin’s lymphoma and was associated with a higher incidence of hypogammaglobulinemia and, potentially, more episodes of infection. (Funded by the Clinical Research Hospital Program of the French Ministry of Health and others; ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT01516580" target="_blank">NCT01516580</a>.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph"><a id="exam-tint-one-a"></a><a id="exam-tint-one-c"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-c">Cure rates among children and adolescents with high-grade, mature B-cell non-Hodgkin’s lymphoma (mainly Burkitt’s lymphoma but also diffuse large B-cell lymphoma) have dramatically improved over the past 30 years, with trials showing survival of approximately 90%.</span><sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3 r4" id="body-ref-r4-1" href-manipulated="true">1-4</a></sup> However, well-known prognostic factors such as higher stage, elevated lactate dehydrogenase (LDH) level, leukemic bone marrow, and central nervous system (CNS) involvement and treatment-related factors such as lack of early or complete response can identify patients at high risk for treatment failure.</div><div role="paragraph"><a id="exam-tint-one-b"></a><a id="exam-tint-one-d"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="one-b one-d">Rituximab has shown efficacy in adults with B-cell cancers, including diffuse large B-cell lymphoma and Burkitt’s lymphoma, and is considered to be the standard of care in addition to chemotherapy in most patients with high-grade B-cell non-Hodgkin’s lymphoma. The outcome in children and adolescents with B-cell non-Hodgkin’s lymphoma receiving chemotherapy alone is superior to that in adults; therefore, the potential benefits of rituximab must be balanced against potential unexpected and severe toxic effects.</span> Furthermore, subtypes of mature B-cell non-Hodgkin’s lymphoma differ between adults and children in terms of molecular anomalies that may confer different prognoses and sensitivities to treatments.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r6" id="body-ref-r6-1" href-manipulated="true">5,6</a></sup></div><div role="paragraph">A phase 2 trial involving children showed that rituximab was active as a single-agent therapy for high-grade, high-risk, mature B-cell non-Hodgkin’s lymphoma and could be safely added to the lymphomes malins B (LMB) chemotherapy regimen.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7-1" href-manipulated="true" aria-label="Reference 7">7</a></sup> Therefore, we conducted an international, randomized, phase 3 trial (Inter-B-NHL ritux 2010) to establish whether the addition of rituximab to LMB chemotherapy could improve event-free survival among children and adolescents with high-grade, high-risk, mature B-cell non-Hodgkin’s lymphoma or leukemia.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Oversight and Design</h3><div role="paragraph">In this trial, we investigated the efficacy and safety of adding rituximab to a modified LMB chemotherapy regimen. This academic trial involved two international cooperative groups — the European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the Children’s Oncology Group (COG) — spanning 12 countries (see the <a href="#ap2">Supplementary Appendix</a>, available with the full text of this article at NEJM.org). The trial sponsors were Gustave Roussy (for countries in the EICNHL) and COG (for Australia, Canada, and the United States) and included a partnership with F. Hoffmann–La Roche–Genentech, which provided partial funding and provided rituximab at no cost but had no role in the design or conduct of the trial nor in the preparation of the manuscript. The manuscript was written by the authors, who vouch for the accuracy and completeness of the data and for the fidelity of the trial to the <a href="#ap1">protocol</a>, available at NEJM.org.</div><div role="paragraph">Parents and patients (if age appropriate) signed informed consent and assent forms before enrollment. The research <a href="#ap1">protocol</a> was approved in each country by the necessary ethics and regulatory committees. An international, independent data and safety monitoring committee, which included two pediatric oncologists, one adult oncologist, and one statistician, monitored progress and interim analysis reports.</div><div role="paragraph">Randomization was performed separately for patients at the EICNHL and COG sites. For patients at the EICHNL sites, randomization was performed centrally at Gustave Roussy with the use of a minimization algorithm that accounted for histologic features (large-cell or non–large-cell), therapeutic group (B, C1, C3; defined in the next subsection), and the national group. To avoid predictability, a probability of 0.80 to assign the treatment that minimized imbalance was used. For patients at the COG sites, randomization was performed centrally at the COG data center, with the use of block randomization stratified according to histologic features and therapeutic group. Physicians and patients were aware of the treatment-group assignments.</div></section><section id="sec-1-2"><h3>Patients</h3><div role="paragraph">Eligible patients were 6 months to 18 years of age and had newly diagnosed high-grade, mature B-cell neoplasms (Burkitt’s lymphoma; diffuse large B-cell lymphoma; or high-grade, mature B-cell non-Hodgkin’s lymphoma not otherwise specified) and advanced St. Jude stage disease (stage III with an LDH level that was more than twice the institutional upper limit of the normal range or any stage IV or leukemia presentation). Patients with primary mediastinal (thymic) large B-cell lymphoma were not eligible. Pathological slides were centrally reviewed at the national level, but centralized review was not mandatory before enrollment. Detailed inclusion and exclusion criteria and initial workup data are provided in the <a href="#ap2">Supplementary Appendix</a>.</div><div role="paragraph">Therapeutic groups were defined as in the French–American–British (FAB)/LMB96 international study for all patients except those with blasts in cerebrospinal fluid (CSF), who were treated with high-dose methotrexate that was administered as a 24-hour infusion (group C3).<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4" id="body-ref-r4-2" href-manipulated="true">3,4</a></sup> The rationale for this modification was a retrospective review of previous LMB studies that showed poorer survival among these patients than among other patients in group C.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8" href-manipulated="true" aria-label="Reference 8">8</a></sup> In the FAB/LMB96 study, outcomes in patients in group B who had stage I, II, or III disease with an LDH level that was equal to or less than twice the upper limit of the normal range were excellent (event-free survival, 95%). Therefore, with regard to group B, only patients who had stage III disease and an LDH level that was more than twice the upper limit of the normal range or non-CNS stage IV disease with bone marrow involvement of less than 25% were eligible for this trial. Patients in group C1 had CSF-negative stage IV disease with bone marrow involvement of at least 25% (leukemia presentation), CNS-positive disease, or both. Group C3 included patients with CSF-positive stage IV disease.</div></section><section id="sec-1-3"><h3>Treatment</h3><div role="paragraph">Chemotherapy was administered according to the FAB/LMB96-based protocol, with some minor modifications (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>).<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4" id="body-ref-r4-3" href-manipulated="true">3,4</a></sup> All the patients received prephase treatment with low-dose cyclophosphamide, vincristine, and prednisone (COP regimen). Patients in group B received four cycles of chemotherapy, which was similar to the therapy used in group B4 in the FAB/LMB96 study. For all the patients in group C, the maintenance chemotherapy was reduced to two courses, in contrast to the four maintenance cycles that were used in the FAB/LMB96 study. Information about monitoring the risk of jeopardizing efficacy with this reduction in therapy is presented in the <a href="#ap2">Supplementary Appendix</a>. Patients in group C1 received high-dose methotrexate (at a dose of 8 g per square meter of body-surface area) over a period of 4 hours, as in the FAB/LMB96 study, whereas patients in group C3 (whose disease was CSF-positive) received high-dose methotrexate (at a dose of 8 g per square meter) over a period of 24 hours. Consecutive courses were administered as soon as blood counts recovered and the patient’s condition allowed, except for the maintenance courses, which were administered at 28-day intervals.</div><div role="paragraph">Rituximab was administered as an intravenous infusion (at a dose of 375 mg per square meter) on day 2 before (i.e., day −2) and day 1 of each of the two induction chemotherapy courses and on day 1 of each of the two consolidation courses, for a total of six doses.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7" id="body-ref-r7-2" href-manipulated="true" aria-label="Reference 7">7</a></sup> When a course had to be postponed, rituximab was administered at the planned time in order to ensure the intensity of the therapy.</div><div role="paragraph">An initial response evaluation was performed on day 7 after the receipt of the COP regimen. Patients in groups B and C1 who had a reduction in the tumor size of less than 20% were switched to a more intensive therapeutic group (i.e., from group B to C1 or from group C1 to C3). Remission assessment was performed after receipt of the first consolidation course in group B and after receipt of the second consolidation course in group C. In patients with a residual mass as assessed by radiographic evaluation, an excision or biopsy for pathological review was recommended. If a biopsy was not performed, the patients were to continue receiving the assigned treatment. For patients in group B, if viable tumor cells were identified, the therapy was switched to the more intensive regimen that was given to patients in group C1. Patients in group C1 or C3 with biopsy-proven viable tumor cells after the second consolidation course (continuous infusion and high-dose cytarabine and etoposide, with or without rituximab [depending on the randomly assigned treatment group]) were considered to have primary refractory disease and were considered to have had an event; such patients discontinued the protocol therapy. No treatment decisions were to be based on the results of <sup>18</sup>F-fluorodeoxyglucose positron-emission tomography–computed tomography.</div></section><section id="sec-1-4"><h3>End Points</h3><div role="paragraph">The primary end point was event-free survival, which was defined as the minimum time between randomization and the detection of residual viable tumor cells after receipt of the second consolidation course of therapy (i.e., primary refractory disease), relapse, progressive disease, second cancer, or death from any cause, or the date of the last follow-up for patients who did not have any event. All events were validated by the steering committee. Details of the secondary end points (overall survival, complete remission at assessment time, toxic effects, and immune reconstitution as assessed by IgG levels) are presented in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">We expected the 3-year event-free survival to be 84% on the basis of data from the FAB/LMB96 study.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4" id="body-ref-r4-4" href-manipulated="true">3,4</a></sup> Because this trial was designed to determine the efficacy of adding rituximab to standard treatment, a one-sided test was used. At a one-sided 5% level of statistical significance and assuming randomization in a 1:1 ratio, we calculated that 72 events would need to be observed in order for the trial to have 90% power to detect a hazard ratio of 0.50 (on the basis of an expected 3-year event-free survival of 84% in the chemotherapy group and 92% in the rituximab–chemotherapy group). It was estimated that 600 patients would need to undergo randomization in order for 72 events to be observed.</div><div role="paragraph">Interim analyses for efficacy with the use of the Lan–DeMets alpha-spending function approach applied to an O’Brien–Fleming boundary, truncated at 3 SD, were planned.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9" href-manipulated="true" aria-label="Reference 9">9</a></sup> The first interim analysis was planned to take place when one third of the total expected events had occurred; the subsequent interim analyses were expected to occur yearly after that.</div><div role="paragraph">Event-free survival and overall survival were estimated by means of the Kaplan–Meier method, and 95% confidence intervals of yearly rates were estimated by the Rothman method. Hazard ratios with adjustment for therapeutic group, histologic type, and national group were estimated by the Cox model. Subgroup analyses according to three baseline characteristics (age, histologic features, and therapeutic group) were prespecified.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Interim Analyses</h3><div role="paragraph">The first interim analysis was based on 27 events in 310 patients, which corresponded to 37.5% of the expected events and a nominal alpha error of 0.00137. The median follow-up was 11.5 months. Event-free survival at 1 year was 94.2% (95% confidence interval [CI], 88.5 to 97.2) in the rituximab–chemotherapy group and 81.5% (95% CI, 73.0 to 87.8) in the chemotherapy group (hazard ratio for event [defined as primary refractory disease or first occurrence of progression, relapse after response, death from any cause, or second cancer], 0.33; 95% CI, 0.14 to 0.79).<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10" href-manipulated="true" aria-label="Reference 10">10</a></sup> The full results of this interim analysis are presented in the <a href="#ap2">Supplementary Appendix</a>.</div><div role="paragraph">After the first interim analysis, randomization was stopped for efficacy in November 2015 on the recommendation of the independent data and safety monitoring committee. An additional 120 patients were subsequently enrolled and treated with rituximab and chemotherapy (single-group cohort) for prespecified secondary aims; these patients are not included in the analyses presented here. The current analyses are based on 38 events, corresponding to 52.8% of the expected events and a nominal alpha error of 0.00562. The cumulative alpha error is 0.00699.</div></section><section id="sec-2-2"><h3>Analysis Sets</h3><div role="paragraph">From December 2011 through November 2015, a total of 362 patients were enrolled at 176 centers. Data from 1 patient were removed owing to withdrawal of consent. The 33 patients who were still receiving induction or consolidation chemotherapy after the closure of randomization in November 2015 were recommended to receive rituximab and chemotherapy regardless of the randomly assigned group. These patients were not included in the primary analysis but were included in the sensitivity analysis. Thus, the main analyses included 328 patients who had undergone randomization until August 26, 2015 (<a href="#f1">Figure 1</a>), including 4 patients who were declared to be ineligible: 3 patients after central pathological review (1 patient had precursor B-cell acute lymphoblastic leukemia and 2 had primary mediastinal B-cell lymphoma) and 1 patient who had stage III disease and an LDH level that was less than two times the upper limit of the normal range.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915315_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915315_f1.jpg"><img src="/cms/10.1056/NEJMoa1915315/asset/2b0f3dff-a893-4615-a023-46366d995877/assets/images/large/nejmoa1915315_f1.jpg" height="2895" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Randomization, Treatment, and Follow-up of the Patients.</div><div class="notes"><div role="doc-footnote">The 33 patients who were still receiving induction or consolidation chemotherapy after the closure of randomization in November 2015 were recommended to receive rituximab and chemotherapy regardless of the randomly assigned group; these patients were not included in the main analyses. ALL denotes acute lymphoblastic leukemia, LDH lactate dehydrogenase, PMBL primary mediastinal B-cell lymphoma, and ULN upper limit of the normal range.</div></div></figcaption></figure></div></section><section id="sec-2-3"><h3>Patients and Treatment</h3><div role="paragraph">The characteristics of the patients at baseline were well balanced between the two treatment groups (<a href="#t1">Table 1</a>). A total of 85.7% of the patients had Burkitt’s lymphoma. Three patients in the chemotherapy group received rituximab (2 owing to physicians’ decisions and 1 because of a diagnosis of primary mediastinal B-cell lymphoma). All the patients in the rituximab–chemotherapy group received rituximab, with 11 patients (7%) receiving fewer than six doses (Table S1).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915315_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915315_t1.jpg"><img src="/cms/10.1056/NEJMoa1915315/asset/da3a8dc0-e43b-4b52-84d7-f0e8f26c5050/assets/images/large/nejmoa1915315_t1.jpg" height="2825" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Chemotherapy Group<br>(N=164)</th><th class="txxr-borders">Rituximab–Chemotherapy Group<br>(N=164)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders shading">137 (83.5)</td><td class="xxxr-borders shading">135 (82.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Age</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Mean — yr</td><td class="xxxx-borders shading">8.6±4.4</td><td class="xxxr-borders shading">9.2±4.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Range — yr</td><td class="xxxx-borders">2–17</td><td class="xxxr-borders">2–17</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Distribution — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">&lt;6 yr</td><td class="xxxx-borders">56 (34.1)</td><td class="xxxr-borders">44 (26.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">6 to &lt;12 yr</td><td class="xxxx-borders shading">67 (40.9)</td><td class="xxxr-borders shading">73 (44.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">12 to &lt;15 yr</td><td class="xxxx-borders">22 (13.4)</td><td class="xxxr-borders">30 (18.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">≥15 yr</td><td class="xxxx-borders shading">19 (11.6)</td><td class="xxxr-borders shading">17 (10.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Pathological diagnosis<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Burkitt’s lymphoma</td><td class="xxxx-borders shading">142 (86.6)</td><td class="xxxr-borders shading">139 (84.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Diffuse large B-cell lymphoma</td><td class="xxxx-borders">12 (7.3)</td><td class="xxxr-borders">19 (11.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">High-grade B-cell lymphoma, not otherwise specified</td><td class="xxxx-borders shading">7 (4.3)</td><td class="xxxr-borders shading">6 (3.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Primary mediastinal B-cell lymphoma<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">2 (1.2)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Precursor B-cell acute lymphoblastic leukemia<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">1 (0.6)</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Prognosis group</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Group B, low risk<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">1 (0.6)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Group B, high risk</td><td class="xxxx-borders">82 (50.0)</td><td class="xxxr-borders">81 (49.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Group C1, without CSF blasts</td><td class="xxxx-borders shading">63 (38.4)</td><td class="xxxr-borders shading">65 (39.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Group C3, with CSF blasts</td><td class="xxxx-borders">16 (9.8)</td><td class="xxxr-borders">18 (11.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Primary mediastinal B-cell lymphoma<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">2 (1.2)</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Murphy stage</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Stage III</td><td class="xxxx-borders shading">73 (44.5)</td><td class="xxxr-borders shading">70 (42.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Stage IV</td><td class="xxxx-borders">32 (19.5)</td><td class="xxxr-borders">32 (19.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Leukemic disease, mature B-cell acute leukemia</td><td class="xxxx-borders shading">57 (34.8)</td><td class="xxxr-borders shading">62 (37.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Primary mediastinal B-cell lymphoma<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">2 (1.2)</td><td class="xxxr-borders">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Central nervous system involvement</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">No</td><td class="xxxx-borders">120 (73.2)</td><td class="xxxr-borders">119 (72.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Yes</td><td class="xxxx-borders shading">44 (26.8)</td><td class="xxxr-borders shading">45 (27.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Lactate dehydrogenase</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">≤2× ULN</td><td class="xxxx-borders shading">18 (11.0)</td><td class="xxxr-borders shading">17 (10.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">&gt;2× ULN</td><td class="xxxx-borders">146 (89.0)</td><td class="xxxr-borders">147 (89.6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Primary site or type</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Thorax</td><td class="xxxx-borders">6 (3.7)</td><td class="xxxr-borders">6 (3.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Abdomen or retroperitoneum</td><td class="xxxx-borders shading">95 (57.9)</td><td class="xxxr-borders shading">96 (58.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Head and neck, except skin and nodes</td><td class="xxxx-borders">9 (5.5)</td><td class="xxxr-borders">20 (12.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Peripheral lymph node</td><td class="xxxx-borders shading">6 (3.7)</td><td class="xxxr-borders shading">2 (1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Cerebral lymphoma</td><td class="xxxx-borders">3 (1.8)</td><td class="xxxr-borders">2 (1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Other tumor site</td><td class="xxxx-borders shading">11 (6.7)</td><td class="xxxr-borders shading">8 (4.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13" data-xml-align="left">Clinical presentation of leukemia disease</td><td class="xbxx-borders">34 (20.7)</td><td class="xbxr-borders">30 (18.3)</td></tr></tbody></table></div><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Percentages may not total 100 because of rounding. CSF denotes cerebrospinal fluid, and ULN upper limit of the normal range (according to institutional values).</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">These data were obtained from national pathological review in 235 patients (72%) or from local pathological diagnosis.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Patients with these conditions were not eligible for the trial. On central review, these patients were found to be ineligible, but they were included in the intention-to-treat analyses.</div></div></div></figcaption></figure></div></section><section id="sec-2-4"><h3>Efficacy</h3><div role="paragraph">The median follow-up was 39.9 months overall, with follow-up of 40.9 months (interquartile range, 35.1 to 48.9) in the rituximab–chemotherapy group and 39.1 months (interquartile range, 34.3 to 49.0) in the chemotherapy group. Data regarding the response after the administration of the COP regimen and remission at the time of assessment are shown in Table S2. In the primary analysis, there were 38 events: 10 in the rituximab–chemotherapy group and 28 in the chemotherapy group (<a href="#t2">Table 2</a>). Six patients (three in each group) died from toxic events. Four patients (two in each group) had primary refractory disease. The major between-group difference in events was observed in relapse or progression, which occurred in 3 patients in the rituximab–chemotherapy group and in 23 in the chemotherapy group; all events of relapse or progression occurred within 9 months after randomization. A total of 18 of these patients subsequently died: all 3 of the patients in the rituximab–chemotherapy group and 15 of the 23 patients in the chemotherapy group. A second cancer developed in 2 patients in the rituximab–chemotherapy group: 1 patient had melanoma, and 1 had fatal histiocytic sarcoma with a t(8;14) <i>IGH</i>–<i>MYC</i> anomaly identical to the primary lymphoma. In total, 8 patients in the rituximab–chemotherapy group died (4 deaths were disease-related, 3 were treatment-related, and 1 was from a second cancer), as did 20 in the chemotherapy group (17 deaths were disease-related, and 3 were treatment-related).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915315_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915315_t2.jpg"><img src="/cms/10.1056/NEJMoa1915315/asset/7e4ac3e3-f671-49da-854a-317570088b76/assets/images/large/nejmoa1915315_t2.jpg" height="2733" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="xxxx-borders" data-xml-align="left">Variable</th><th class="xxxx-borders" colspan="3"><span>Chemotherapy Group</span></th><th class="xxxx-borders" colspan="3"><span>Rituximab–Chemotherapy Group</span></th></tr><tr class="head2" data-type="row head2"><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">No. of<br>Patients</th><th class="xxxx-borders">No. of Patients<br>with Event</th><th class="xxxx-borders">No. of<br>Deaths</th><th class="xxxx-borders">No. of<br>Patients</th><th class="xxxx-borders">No. of Patients<br>with Event</th><th class="xxxx-borders">No. of<br>Deaths</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02 shading" data-xml-align="left">All patients</td><td class="xxxx-borders shading">164</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">164</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Death from toxic event</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">3</td><td class="xxxx-borders">3</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">3</td><td class="xxxx-borders">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Primary refractory disease, with viable cells after CYVE2 therapy</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Relapse or progression</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">23</td><td class="xxxx-borders">15</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">3</td><td class="xxxx-borders">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Second cancer</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Total no. of events</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">28</td><td class="xxxx-borders">—</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">10</td><td class="xxxx-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Total no. of deaths</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">20</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02" data-xml-align="left">Group B</td><td class="xxxx-borders">84<a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">81</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Death from toxic event</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">2<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Primary refractory disease, with viable cells after CYVE2 therapy</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1</td><td class="xxxx-borders">1</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Relapse or progression</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">11</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Second cancer</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Total no. of events</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">14</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Total no. of deaths</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">—</td><td class="xxxx-borders">9</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">—</td><td class="xxxx-borders">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02 shading" data-xml-align="left">Group C1</td><td class="xxxx-borders shading">64<a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">65</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Death from toxic event</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1</td><td class="xxxx-borders">1</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">3</td><td class="xxxx-borders">3<a href="#t2fn6" role="doc-noteref">‖</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Primary refractory disease, with viable cells after CYVE2 therapy</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Relapse or progression</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">8</td><td class="xxxx-borders">5</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Second cancer</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Total no. of events</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">10</td><td class="xxxx-borders">—</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">4</td><td class="xxxx-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Total no. of deaths</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">7</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02" data-xml-align="left">Group C3</td><td class="xxxx-borders">16</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">18</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Death from toxic event</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Primary refractory disease, with viable cells after CYVE2 therapy</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Relapse or progression</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">4</td><td class="xxxx-borders shading">4</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Second cancer</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1</td><td class="xxxx-borders">1<a href="#t2fn7" role="doc-noteref">**</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Total no. of events</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">4</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Total no. of deaths</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">—</td><td class="xxxx-borders">4</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">—</td><td class="xxxx-borders">1</td></tr></tbody></table></div><figcaption><div class="caption">Number and Type of Events and Number of Deaths.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">CYVE2 denotes the second course of continuous infusion and high-dose cytarabine and etoposide.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">One patient in the low-risk group B (who did not have an event) was counted in group B.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">One patient who was receiving group C1 chemotherapy died after receipt of the first course of therapy with cyclophosphamide, vincristine, prednisone, doxorubicin, and methotrexate.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">One patient, a 14-year-old girl, received a diagnosis of melanoma that had developed on a congenital skin nevus 5 months after the diagnosis of Burkitt’s lymphoma.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t2fn5" role="paragraph">One patient with primary mediastinal B-cell lymphoma (who did not have an event) was counted in group B, and one (who had disease progression) was counted in group C1.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t2fn6" role="paragraph">One patient switched to group C3 after receipt of the COP regimen; the death occurred after receipt of the second course of group C3 chemotherapy (cyclophosphamide, vincristine, prednisone, doxorubicin, and methotrexate).</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t2fn7" role="paragraph">One patient, a 6-year-old boy, had fatal histiocytic sarcoma with an identical t(8;14) <i>IGH</i>–<i>MYC</i> anomaly, which had been diagnosed when he was 16.6 months of age.</div></div></div></figcaption></figure></div><div role="paragraph">Event-free survival at 3 years was 93.9% (95% CI, 89.1 to 96.7) in the rituximab–chemotherapy group and 82.3% (95% CI, 75.7 to 87.5) in the chemotherapy group (<a href="#f2">Figure 2A</a>). In the analysis of event-free survival, the hazard ratio for an event was 0.32 (95% CI, 0.15 to 0.66; one-sided P=0.00096, which reached the significance level required for this second analysis). Overall survival at 3 years was 95.1% (95% CI, 90.5 to 97.5) in the rituximab–chemotherapy group and 87.3% (95% CI, 81.2 to 91.6) in the chemotherapy group (hazard ratio for death, 0.36; 95% CI, 0.16 to 0.82) (<a href="#f2">Figure 2B</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915315_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915315_f2.jpg"><img src="/cms/10.1056/NEJMoa1915315/asset/edb14894-f7ee-4ade-81ca-350b1fa1cde6/assets/images/large/nejmoa1915315_f2.jpg" height="3058" width="2231" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Event-free Survival and Overall Survival, According to Treatment Group.</div><div class="notes"><div role="doc-footnote">Shown are Kaplan–Meier estimates of event-free survival (i.e., freedom from primary refractory disease or first occurrence of progression, relapse after response, death from any cause, or second cancer) and of overall survival. Vertical bars represent the Rothman 95% confidence intervals; point estimates of 36-month event-free survival and overall survival with 95% confidence intervals are shown.</div></div></figcaption></figure></div><div role="paragraph">The sensitivity analysis, which involved 361 patients (including those in the period between August 26, 2015, and November 2015, who were recommended to receive rituximab and chemotherapy regardless of the randomly assigned group), showed similar results. Event-free survival at 3 years was 92.8% in the rituximab–chemotherapy group and 83.4% in the chemotherapy group (hazard ratio for an event, 0.40; 95% CI, 0.21 to 0.78). Overall survival at 3 years was 94.3% in the rituximab–chemotherapy group and 88.5% in the chemotherapy group (hazard ratio for death, 0.45; 95% CI, 0.21 to 0.97). The benefit of rituximab was similar across subgroups defined according to age, histologic features, and therapeutic group (Fig. S2).</div></section><section id="sec-2-5"><h3>Adverse Events</h3><div role="paragraph">The incidence of rituximab infusion–related reactions was 33.3% during the first infusion (with 4.3% of the patients having a grade 3 event); the incidence decreased to 3.7 to 9.6% during subsequent infusions (with 1.0 to 2.1% of the patients having a grade 3 event). No immediate infusion-related grade 4 toxic effect occurred. Treatment-related toxic effects of grade 4 or higher were observed in 35.2% of the patients overall, including in 28.9% of the patients after prephase treatment with the COP regimen (<a href="#t3">Table 3</a>). The most frequent adverse events after prephase treatment were febrile neutropenia (in 91.7% of the patients), infection (in 54.0%), and stomatitis (in 77.5%).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915315_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915315_t3.jpg"><img src="/cms/10.1056/NEJMoa1915315/asset/aa2899de-a4c3-4a9d-9be4-182744a20023/assets/images/large/nejmoa1915315_t3.jpg" height="2668" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders">All Patients<br>(N=315)</th><th class="txxx-borders">Chemotherapy Group<br>(N=153)</th><th class="txxx-borders">Rituximab–Chemotherapy Group<br>(N=162)</th><th class="txxr-borders">P Value</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="3"><span>no. of patients (%)</span></th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading"><b>During all therapy</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">≥1 Adverse event</td><td class="xxxx-borders">306 (97.1)</td><td class="xxxx-borders">148 (96.7)</td><td class="xxxx-borders">158 (97.5)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">≥1 Adverse event of grade ≥4</td><td class="xxxx-borders shading">111 (35.2)</td><td class="xxxx-borders shading">50 (32.7)</td><td class="xxxx-borders shading">61 (37.7)</td><td class="xxxr-borders shading">0.36</td></tr><tr data-type="row"><td class="xxlx-borders hanging03"><b>During COP prephase treatment</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">≥1 Adverse event</td><td class="xxxx-borders shading">63 (20.0)</td><td class="xxxx-borders shading">31 (20.3)</td><td class="xxxx-borders shading">32 (19.8)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">≥1 Adverse event of grade ≥4</td><td class="xxxx-borders">27 (8.6)</td><td class="xxxx-borders">17 (11.1)</td><td class="xxxx-borders">10 (6.2)</td><td class="xxxr-borders">0.12</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading"><b>After COP prephase treatment</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">≥1 Adverse event</td><td class="xxxx-borders">303 (96.2)</td><td class="xxxx-borders">147 (96.1)</td><td class="xxxx-borders">156 (96.3)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">≥1 Adverse event of grade ≥4</td><td class="xxxx-borders shading">91 (28.9)</td><td class="xxxx-borders shading">37 (24.2)</td><td class="xxxx-borders shading">54 (33.3)</td><td class="xxxr-borders shading">0.07</td></tr><tr data-type="row"><td class="xxlx-borders hanging03"><b>Most frequent adverse events after COP prephase treatment</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Febrile neutropenia</td><td class="xxxx-borders shading">289 (91.7)</td><td class="xxxx-borders shading">139 (90.8)</td><td class="xxxx-borders shading">150 (92.6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Grade 3</td><td class="xxxx-borders">260 (82.5)</td><td class="xxxx-borders">129 (84.3)</td><td class="xxxx-borders">131 (80.9)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Grade ≥4</td><td class="xxxx-borders shading">29 (9.2)</td><td class="xxxx-borders shading">10 (6.5)</td><td class="xxxx-borders shading">19 (11.7)</td><td class="xxxr-borders shading">0.11</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Stomatitis</td><td class="xxxx-borders">244 (77.5)</td><td class="xxxx-borders">115 (75.2)</td><td class="xxxx-borders">129 (79.6)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Grade 3</td><td class="xxxx-borders shading">224 (71.1)</td><td class="xxxx-borders shading">108 (70.6)</td><td class="xxxx-borders shading">116 (71.6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Grade ≥4</td><td class="xxxx-borders">20 (6.3)</td><td class="xxxx-borders">7 (4.6)</td><td class="xxxx-borders">13 (8.0)</td><td class="xxxr-borders">0.21</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Enteritis</td><td class="xxxx-borders shading">63 (20.0)</td><td class="xxxx-borders shading">24 (15.7)</td><td class="xxxx-borders shading">39 (24.1)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Grade 3</td><td class="xxxx-borders">62 (19.7)</td><td class="xxxx-borders">24 (15.7)</td><td class="xxxx-borders">38 (23.5)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Grade ≥4</td><td class="xxxx-borders shading">1 (0.3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.6)</td><td class="xxxr-borders shading">1.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Infection</td><td class="xxxx-borders">170 (54.0)</td><td class="xxxx-borders">75 (49.0)</td><td class="xxxx-borders">95 (58.6)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Grade 3</td><td class="xxxx-borders shading">123 (39.0)</td><td class="xxxx-borders shading">58 (37.9)</td><td class="xxxx-borders shading">65 (40.1)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Grade ≥4</td><td class="xxxx-borders">47 (14.9)</td><td class="xxxx-borders">17 (11.1)</td><td class="xxxx-borders">30 (18.5)</td><td class="xxxr-borders">0.07</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Main types of infection</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Sepsis</td><td class="xxxx-borders">45 (14.3)</td><td class="xxxx-borders">17 (11.1)</td><td class="xxxx-borders">28 (17.3)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Central venous catheter– related infection</td><td class="xxxx-borders shading">38 (12.1)</td><td class="xxxx-borders shading">17 (11.1)</td><td class="xxxx-borders shading">21 (13.0)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Lung infection</td><td class="xxxx-borders">32 (10.2)</td><td class="xxxx-borders">13 (8.5)</td><td class="xxxx-borders">19 (11.7)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Enterocolitis infection</td><td class="xxxx-borders shading">32 (10.2)</td><td class="xxxx-borders shading">18 (11.8)</td><td class="xxxx-borders shading">14 (8.6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Biologic adverse events</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Alanine aminotransferase increased</td><td class="xxxx-borders shading">41 (13.0)</td><td class="xxxx-borders shading">18 (11.8)</td><td class="xxxx-borders shading">23 (14.2)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Grade 3</td><td class="xxxx-borders">25 (7.9)</td><td class="xxxx-borders">12 (7.8)</td><td class="xxxx-borders">13 (8.0)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Grade ≥4</td><td class="xxxx-borders shading">16 (5.1)</td><td class="xxxx-borders shading">6 (3.9)</td><td class="xxxx-borders shading">10 (6.2)</td><td class="xxxr-borders shading">0.36</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Hypokalemia</td><td class="xxxx-borders">36 (11.4)</td><td class="xxxx-borders">15 (9.8)</td><td class="xxxx-borders">21 (13.0)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Grade 3</td><td class="xxxx-borders shading">28 (8.9)</td><td class="xxxx-borders shading">11 (7.2)</td><td class="xxxx-borders shading">17 (10.5)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging23" data-xml-align="left">Grade ≥4</td><td class="xbxx-borders">8 (2.5)</td><td class="xbxx-borders">4 (2.6)</td><td class="xbxx-borders">4 (2.5)</td><td class="xbxr-borders">1.00</td></tr></tbody></table></div><figcaption><div class="caption">Acute Adverse Events.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Shown are the numbers and percentages of patients who had at least one adverse event, those who had at least one adverse event of grade 4 or higher, and those who had the most frequent acute adverse events (i.e., events occurring in &gt;10% of the patients overall). A total of 13 patients who did not have data on treatment or adverse events or who received only prephase treatment (a regimen of cyclophosphamide, vincristine, and prednisone [COP]) were not included in this analysis. Only nonhematologic adverse events of grade 3 or higher or cardiac adverse events of grade 2 or higher were recorded. P values are shown for events of grade 4 or higher.</div></div></div></figcaption></figure></div><div role="paragraph">Six patients (1.8% of the patients overall; three patients in each group) died from toxic effects. Five of the deaths, four of which were from infection, occurred in patients receiving group C chemotherapy after the receipt of the first course of therapy with cyclophosphamide, vincristine, prednisone, doxorubicin, and methotrexate, with or without rituximab depending on treatment group (in three patients); after the receipt of the second course of therapy with cyclophosphamide, vincristine, prednisone, doxorubicin, and methotrexate, with rituximab (in one patient); or after the receipt of a continuous infusion and high-dose cytarabine and etoposide, with rituximab (in one patient). One death from toxic effects occurred in a patient receiving group B chemotherapy who had undergone hemicolectomy at diagnosis and died from small-bowel obstruction and septic shock after the receipt of COPADM2.</div><div role="paragraph">The incidence of adverse events of grade 4 or higher was 37.7% in the rituximab–chemotherapy group and 32.7% in the chemotherapy group (P=0.36). In an analysis that was focused on the period after the receipt of COP prephase treatment, the incidence of adverse events of grade 4 or higher was 33.3% in the rituximab–chemotherapy group and 24.2% in the chemotherapy group (P=0.07). After prephase treatment, the incidence of febrile neutropenia of grade 4 or higher was 11.7% in the rituximab–chemotherapy group and 6.5% in the chemotherapy group (P=0.11), and the incidence of infection of grade 4 or higher was 18.5% and 11.1%, respectively (P=0.07). No other acute unexpected toxic effects were reported in either group. The most frequent adverse events according to treatment course and all adverse events of grade 4 or higher are presented in Tables S3 and S4, respectively.</div></section><section id="sec-2-6"><h3>Immunoglobulin Status</h3><div role="paragraph">The percentage of patients with a low IgG level (less than the lower limit of the normal range) was significantly higher in the rituximab–chemotherapy group than in the chemotherapy group at the end of therapy (70.3% vs. 46.8%, P=0.002) and at 1 year after inclusion (55.9% vs. 25.4%, P&lt;0.001), respectively (Table S5). Approximately twice as many patients in the rituximab–chemotherapy group as in the chemotherapy group received intravenous immune globulin (15.8% vs. 7.0%). The primary reason for immune globulin replacement was a low immunoglobulin level without infection (Table S6). At 1 year after enrollment, seven patients were still receiving intravenous immune globulin in the rituximab–chemotherapy group and three in the chemotherapy group. Complete and longer follow-up with regard to immune status and late infections have not been evaluated.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph"><a id="exam-tint-two-a"></a><a id="exam-tint-two-b"></a><a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-c two-d">In this randomized, international, phase 3 trial, we found that among children and adolescents with high-grade, high-risk, mature B-cell lymphoma, the addition of six doses of rituximab to LMB therapy led to significantly better event-free survival outcomes (hazard ratio for an event, 0.32; 95% CI, 0.15 to 0.66; 3-year event-free survival, 93.9% in the rituximab–chemotherapy group vs. 82.3% in the chemotherapy group). The benefit was similar across the various therapeutic groups, including the group of patients with CNS disease. Higher 3-year overall survival was also observed (95.1% in the rituximab–chemotherapy group vs. 87.3% in the chemotherapy group; hazard ratio for death, 0.36; 95% CI, 0.16 to 0.82).</span> <a id="exam-tint-three-a"></a><a id="exam-tint-three-b"></a><a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-c three-d">Overall, the acute toxic effects that were associated with the addition of rituximab mainly involved a higher incidence of myelotoxic effects, but further follow-up is needed to provide information on long-term safety because rituximab therapy induced more hypogammaglobulinemia than chemotherapy alone.</span></div><div role="paragraph">The benefit of rituximab therapy in this trial appeared to be similar to that observed in trials involving adult patients. In a randomized French trial that compared the addition of four doses of rituximab to adult-adapted LMB chemotherapy with chemotherapy alone in 257 patients with Burkitt’s lymphoma (61% of the patients were ≥40 years of age), superior 3-year event-free survival (75% in the rituximab–chemotherapy group vs. 62% in the chemotherapy group; hazard ratio for event, 0.59; P=0.02) and overall survival (83% vs. 70%; hazard ratio for death, 0.51; P=0.01) were observed.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11" href-manipulated="true" aria-label="Reference 11">11</a></sup> A direct comparison of outcomes in adults and children is difficult, however, because the outcomes in children who are treated with chemotherapy are superior to those in adults, and molecular analyses suggest that there is age-related biologic heterogeneity in Burkitt’s lymphomagenesis.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r6" id="body-ref-r6-2" href-manipulated="true">5,6</a></sup></div><div role="paragraph">The data from this trial suggest that the addition of rituximab may result in a higher incidence of severe (grade ≥4) acute adverse events (primarily febrile neutropenia and infection) after prephase treatment. Although specific viral infections have been reported in approximately 2% of patients treated with rituximab, we did not observe such infections in the rituximab–chemotherapy group (which included 164 patients), but longer follow-up is needed.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12 r13" id="body-ref-r13" href-manipulated="true">12,13</a></sup> Two patients (1%) in the rituximab–chemotherapy group had second cancers: one patient had melanoma within a congenital skin nevus, and one patient had a clonally related histiocytic sarcoma suggesting transdifferentiation of the Burkitt’s lymphoma clone. Some reports have suggested that among adult patients with lymphoma, the introduction of rituximab may increase the risk of a second cancer (especially acute myeloid leukemia, thyroid cancer, and melanoma),<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14" href-manipulated="true" aria-label="Reference 14">14</a></sup> but a meta-analysis did not support this finding.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15" href-manipulated="true" aria-label="Reference 15">15</a></sup> Finally, approximately twice as many patients in the rituximab–chemotherapy group as in the chemotherapy group had a low IgG level 1 year after trial inclusion, although very few patients received immune globulin replacement for infections. An assessment of the long-term effects of combining rituximab with this chemotherapy regimen in children with non-Hodgkin’s lymphoma, including data on immune status, will be useful.</div><div role="paragraph">A previous phase 2 window study involving children with newly diagnosed high-grade, mature B-cell non-Hodgkin’s lymphoma showed that 21% of the patients had a complete or partial response during a 5-day window after receiving a single dose of rituximab<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16" href-manipulated="true" aria-label="Reference 16">16</a></sup>; another study is currently comparing one dose of rituximab with six doses in children with advanced-stage B-cell non-Hodgkin’s lymphoma (ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03206671" target="_blank">NCT03206671</a>). With respect to pharmacokinetics, rituximab clearance appears to be related to total tumor burden; exposure to rituximab decreases as tumor metabolic volume increases. Higher rituximab exposure is associated with a higher percentage of patients with a response and longer progression-free survival among patients with diffuse large B-cell lymphoma.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17" href-manipulated="true" aria-label="Reference 17">17</a></sup> A small cohort study involving children and adolescents with high-grade, mature B-cell non-Hodgkin’s lymphoma showed some age dependency with regard to rituximab pharmacokinetics.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup> Thus, we are conducting additional pharmacokinetic analyses, including examination of the effects of age and tumor burden on rituximab disposition.</div><div role="paragraph">Although the results of the Inter-B-NHL ritux 2010 trial showed a benefit with the addition of rituximab in the treatment of children with high-grade, high-risk, mature B-cell non-Hodgkin’s lymphoma, the use of rituximab in children with standard-risk B-cell non-Hodgkin’s lymphoma (approximately 40% of patients) is still questionable, because their survival after treatment with chemotherapy alone is very high (97 to 98%).<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19" href-manipulated="true" aria-label="Reference 19">19</a></sup> It is conceivable that the addition of rituximab could allow for a reduction of cytotoxic chemotherapy; however, given the very poor outcome in patients with refractory or relapsed disease,<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20" href-manipulated="true" aria-label="Reference 20">20</a></sup> it would be ethically challenging to conduct such a study. Furthermore, although current chemotherapy is associated with substantial acute toxic effects, deaths from toxic effects are rare and the risks of clinically significant long-term sequelae are relatively modest with the use of this chemotherapy backbone.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21" id="body-ref-r21" href-manipulated="true" aria-label="Reference 21">21</a></sup> To help inform such a study, more data are necessary in order to evaluate the long-term safety of rituximab administered with chemotherapy in children with non-Hodgkin’s lymphoma.</div><div role="paragraph">This trial showed that the addition of rituximab to chemotherapy was effective therapy in children and adolescents with high-risk, high-grade, mature B-cell non-Hodgkin’s lymphoma and resulted in long-term complete remission in 95% of the patients. In addition, we found an effective global framework for academic-based, collaborative pediatric groups that leveraged both public and private sector support to conduct clinical trials involving children with a rare cancer.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by a grant (PHRC2010) from the Clinical Research Hospital Program of the <span class="named-content" data-type="funder">French Ministry of Health</span>, by <span class="named-content" data-type="funder">Cancer Research UK</span>, the <span class="named-content" data-type="funder">National Institute for Health Research Clinical Research Network</span>, and <span class="named-content" data-type="funder">Children’s Cancer Foundation Hong Kong</span>, by grants (U10CA180886 and U10CA180899) from the U.S. <span class="named-content" data-type="funder">National Cancer Institute</span>, and by F. Hoffmann–La Roche–Genentech.</div><div role="paragraph">Dr. Minard-Colin reports receiving grant support, paid to her institution, from F. Hoffmann–La Roche; Dr. Aupérin, receiving grant support, paid to her institution, from F. Hoffmann–La Roche; Dr. Burke, receiving consulting fees from F. Hoffmann–La Roche, Janssen Pharmaceuticals, Merck, and Takeda Pharmaceutical; Dr. Adamson, receiving grant support, paid to Children’s Hospital of Philadelphia, from Roche Genentech, owning stock in Merck, and being employed by Sanofi and Genzyme US; Dr. Vassal, receiving grant support, paid to his institution, from F. Hoffmann–La Roche; and Dr. Patte, receiving grant support, paid to her institution, from F. Hoffmann–La Roche. No other potential conflict of interest relevant to this article was reported.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the members of the national and international review panels (P. Dartigues, T. Molina, J. Bosq, S. Perkins, K. McCarthy, A. Ferrández, O. Balagué, F. Loong, J.C. So, and E.S.G. d’Amore); all the European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and Children’s Oncology Group (COG) committee members and investigators who participated in the trial; F. Rotolo, of the Gustave Roussy Unit of Biostatistics and Epidemiology; the national data managers (R. Banusz, E. Carraro, A. Raxworthy Cooper, V. Femke, O. Hung, A. Michiels, M. Peiró, J. Vreijling, O. Wajsen, and T. Yu); G. Goma and A. Mangin for data management for the patients at the EICNHL sites; J. Anderson, A. Buxton, D. Hall, L. Saguilig, A. Miranda, T. Hlaing, and G. Galit for data management for the patients at the COG sites; A. Tulard, D. Vuillier, and J. Rubino, of the Gustave Roussy clinical research team; S. Laghouati for pharmacovigilance; the members of the independent data and safety monitoring board (R. Sposto, F. Pein, R. Pinkerton, and M. Robert); and the F. Hoffmann–La Roche–Genentech team. This study was initially proposed to the Paediatric Committee by the Marketing Authorisation Holder on May 13, 2009, as the sole measure in the MabThera PIP (EMEA-000308-PIP01-08). The initial MabThera PIP was submitted on June 28, 2008, and was agreed on in the European Medicines Agency decision adopted on July 14, 2009.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa1915315_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1915315/suppl_file/nejmoa1915315_protocol.pdf" download="nejmoa1915315_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1915315_protocol.pdf" data-doi="10.1056/NEJMoa1915315">Download</a></li><li>2.28 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa1915315_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1915315/suppl_file/nejmoa1915315_appendix.pdf" download="nejmoa1915315_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1915315_appendix.pdf" data-doi="10.1056/NEJMoa1915315">Download</a></li><li>893.40 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa1915315_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1915315/suppl_file/nejmoa1915315_disclosures.pdf" download="nejmoa1915315_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1915315_disclosures.pdf" data-doi="10.1056/NEJMoa1915315">Download</a></li><li>423.33 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa1915315_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1915315/suppl_file/nejmoa1915315_data-sharing.pdf" download="nejmoa1915315_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1915315_data-sharing.pdf" data-doi="10.1056/NEJMoa1915315">Download</a></li><li>71.44 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Minard-Colin V, Brugières L, Reiter A, et al. Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. <em>J Clin Oncol</em> 2015;33:2963-2974.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2014.59.5827" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26304908/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000366018800004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Non-Hodgkin+lymphoma+in+children+and+adolescents%3A+progress+through+effective+collaboration%2C+current+knowledge%2C+and+challenges+ahead.&amp;publication_year=2015&amp;journal=J+Clin+Oncol&amp;pages=2963-2974&amp;doi=10.1200%2FJCO.2014.59.5827&amp;pmid=26304908" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. <em>Blood</em> 2005;105:948-958.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2004-03-0973" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15486066/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000226596700016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+impact+of+the+methotrexate+administration+schedule+and+dose+in+the+treatment+of+children+and+adolescents+with+B-cell+neoplasms%3A+a+report+of+the+BFM+Group+Study+NHL-BFM95.&amp;publication_year=2005&amp;journal=Blood&amp;pages=948-958&amp;doi=10.1182%2Fblood-2004-03-0973&amp;pmid=15486066" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. <em>Blood</em> 2007;109:2773-2780.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2006-07-036673" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17132719/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000245639000025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Results+of+the+randomized+international+FAB%2FLMB96+trial+for+intermediate+risk+B-cell+non-Hodgkin+lymphoma+in+children+and+adolescents%3A+it+is+possible+to+reduce+treatment+for+the+early+responding+patients.&amp;publication_year=2007&amp;journal=Blood&amp;pages=2773-2780&amp;doi=10.1182%2Fblood-2006-07-036673&amp;pmid=17132719" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] showing survival of approximately 90%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] as a 24-hour infusion (group C3). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] Supplementary Appendix). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] the basis of data from the FAB/LMB96 study. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. <em>Blood</em> 2007;109:2736-2743.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2006-07-036665" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17138821/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000245639000020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Results+of+a+randomized+international+study+of+high-risk+central+nervous+system+B+non-Hodgkin+lymphoma+and+B+acute+lymphoblastic+leukemia+in+children+and+adolescents.&amp;publication_year=2007&amp;journal=Blood&amp;pages=2736-2743&amp;doi=10.1182%2Fblood-2006-07-036665&amp;pmid=17138821" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] showing survival of approximately 90%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] as a 24-hour infusion (group C3). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] Supplementary Appendix). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] the basis of data from the FAB/LMB96 study. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Havelange V, Pepermans X, Ameye G, et al. Genetic differences between paediatric and adult Burkitt lymphomas. <em>Br J Haematol</em> 2016;173:137-144.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.13925" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26887776/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000373138700013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genetic+differences+between+paediatric+and+adult+Burkitt+lymphomas.&amp;publication_year=2016&amp;journal=Br+J+Haematol&amp;pages=137-144&amp;doi=10.1111%2Fbjh.13925&amp;pmid=26887776" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] prognoses and sensitivities to treatments. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] heterogeneity in Burkitt’s lymphomagenesis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">López C, Kleinheinz K, Aukema SM, et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. <em>Nat Commun</em> 2019;10:1459-1459.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41467-019-08578-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30926794/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000462722700006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genomic+and+transcriptomic+changes+complement+each+other+in+the+pathogenesis+of+sporadic+Burkitt+lymphoma.&amp;publication_year=2019&amp;journal=Nat+Commun&amp;pages=1459-1459&amp;doi=10.1038%2Fs41467-019-08578-3&amp;pmid=30926794" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] prognoses and sensitivities to treatments. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] heterogeneity in Burkitt’s lymphomagenesis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report. <em>Leukemia</em> 2013;27:1174-1177.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/leu.2012.255" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22940833/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000318698300022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rituximab+and+FAB%2FLMB+96+chemotherapy+in+children+with+stage+III%2FIV+B-cell+non-Hodgkin+lymphoma%3A+a+Children%E2%80%99s+Oncology+Group+report.&amp;publication_year=2013&amp;journal=Leukemia&amp;pages=1174-1177&amp;doi=10.1038%2Fleu.2012.255&amp;pmid=22940833" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] malins B (LMB) chemotherapy regimen. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] courses, for a total of six doses. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Minard-Colin V, Auperin A, Leverger G. In childhood B-cell non Hodgkin’s lymphoma (B-NHL) and mature B-cell acute leukemia (B-AL) with CNS disease at diagnosis, patients with blasts in CSF are at higher risk of event. <em>Ann Oncol</em> 2011;22:Suppl 4:iv112-iv114.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000291996300101" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=In+childhood+B-cell+non+Hodgkin%E2%80%99s+lymphoma+%28B-NHL%29+and+mature+B-cell+acute+leukemia+%28B-AL%29+with+CNS+disease+at+diagnosis%2C+patients+with+blasts+in+CSF+are+at+higher+risk+of+event.&amp;publication_year=2011&amp;journal=Ann+Oncol&amp;pages=iv112-iv114" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. <em>Stat Med</em> 1994;13:1341-1352.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/sim.4780131308" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7973215/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1994PA16800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interim+analysis%3A+the+alpha+spending+function+approach.&amp;publication_year=1994&amp;journal=Stat+Med&amp;pages=1341-1352&amp;doi=10.1002%2Fsim.4780131308&amp;pmid=7973215" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Minard-Colin V, Auperin A, Pillon M, et al. Results of the randomized Intergroup trial Inter-B-NHL ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen. <em>J Clin Oncol</em> 2016;34:Suppl:10507-10507. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2016.34.15_suppl.10507" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000404712500302" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Results+of+the+randomized+Intergroup+trial+Inter-B-NHL+ritux+2010+for+children+and+adolescents+with+high-risk+B-cell+non-Hodgkin+lymphoma+%28B-NHL%29+and+mature+acute+leukemia+%28B-AL%29%3A+evaluation+of+rituximab+%28R%29+efficacy+in+addition+to+standard+LMB+chemotherapy+%28CT%29+regimen.&amp;publication_year=2016&amp;journal=J+Clin+Oncol&amp;pages=10507-10507&amp;doi=10.1200%2FJCO.2016.34.15_suppl.10507" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, phase 3 trial. <em>Lancet</em> 2016;387:2402-2411.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(15)01317-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27080498/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000377560100033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rituximab+and+dose-dense+chemotherapy+for+adults+with+Burkitt%E2%80%99s+lymphoma%3A+a+randomised%2C+controlled%2C+open-label%2C+phase+3+trial.&amp;publication_year=2016&amp;journal=Lancet&amp;pages=2402-2411&amp;doi=10.1016%2FS0140-6736%2815%2901317-3&amp;pmid=27080498" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Focosi D, Tuccori M, Maggi F. Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: what do we know after 20 years of rituximab. <em>Rev Med Virol</em> 2019;29(6):e2077-e2077.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/rmv.2077" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31369199/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000479823200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Progressive+multifocal+leukoencephalopathy+and+anti-CD20+monoclonal+antibodies%3A+what+do+we+know+after+20+years+of+rituximab.&amp;publication_year=2019&amp;journal=Rev+Med+Virol&amp;pages=e2077-e2077&amp;doi=10.1002%2Frmv.2077&amp;pmid=31369199" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Kusumoto S, Arcaini L, Hong X, et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. <em>Blood</em> 2019;133:137-146.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2018-04-848044" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30341058/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000455409800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+of+HBV+reactivation+in+patients+with+B-cell+lymphomas+receiving+obinutuzumab+or+rituximab+immunochemotherapy.&amp;publication_year=2019&amp;journal=Blood&amp;pages=137-146&amp;doi=10.1182%2Fblood-2018-04-848044&amp;pmid=30341058" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Tao L, Clarke CA, Rosenberg AS, et al. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. <em>Br J Haematol</em> 2017;178:72-80.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.14638" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28542862/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000404042700010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Subsequent+primary+malignancies+after+diffuse+large+B-cell+lymphoma+in+the+modern+treatment+era.&amp;publication_year=2017&amp;journal=Br+J+Haematol&amp;pages=72-80&amp;doi=10.1111%2Fbjh.14638&amp;pmid=28542862" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Fleury I, Chevret S, Pfreundschuh M, et al. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. <em>Ann Oncol</em> 2016;27:390-397.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdv616" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26681685/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000371691600006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rituximab+and+risk+of+second+primary+malignancies+in+patients+with+non-Hodgkin+lymphoma%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2016&amp;journal=Ann+Oncol&amp;pages=390-397&amp;doi=10.1093%2Fannonc%2Fmdv616&amp;pmid=26681685" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Meinhardt A, Burkhardt B, Zimmermann M, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt leukemia. <em>J Clin Oncol</em> 2010;28:3115-3121.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2009.26.6791" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20516455/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000279254300005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+II+window+study+on+rituximab+in+newly+diagnosed+pediatric+mature+B-cell+non-Hodgkin%E2%80%99s+lymphoma+and+Burkitt+leukemia.&amp;publication_year=2010&amp;journal=J+Clin+Oncol&amp;pages=3115-3121&amp;doi=10.1200%2FJCO.2009.26.6791&amp;pmid=20516455" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Tout M, Casasnovas O, Meignan M, et al. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. <em>Blood</em> 2017;129:2616-2623.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2016-10-744292" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28251914/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000400980000008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rituximab+exposure+is+influenced+by+baseline+metabolic+tumor+volume+and+predicts+outcome+of+DLBCL+patients%3A+a+Lymphoma+Study+Association+report.&amp;publication_year=2017&amp;journal=Blood&amp;pages=2616-2623&amp;doi=10.1182%2Fblood-2016-10-744292&amp;pmid=28251914" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Barth MJ, Goldman S, Smith L, et al. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children’s Oncology Group report. <em>Br J Haematol</em> 2013;162:678-683.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.12434" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23802659/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000323158400012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rituximab+pharmacokinetics+in+children+and+adolescents+with+de+novo+intermediate+and+advanced+mature+B-cell+lymphoma%2Fleukaemia%3A+a+Children%E2%80%99s+Oncology+Group+report.&amp;publication_year=2013&amp;journal=Br+J+Haematol&amp;pages=678-683&amp;doi=10.1111%2Fbjh.12434&amp;pmid=23802659" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Patte C, Zimmerman M, Auperin A, Reiter A. Similar results are currently observed in the LMB and BFM studies for B-cell Non-Hodgkin’s lymphoma and B-AL allowing future common studies. <em>Pediatr Blood Cancer</em> 2010;55:795-795. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000282910200075" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Similar+results+are+currently+observed+in+the+LMB+and+BFM+studies+for+B-cell+Non-Hodgkin%E2%80%99s+lymphoma+and+B-AL+allowing+future+common+studies.&amp;publication_year=2010&amp;journal=Pediatr+Blood+Cancer&amp;pages=795-795" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Pearson ADJ, Scobie N, Norga K, et al. ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. <em>Eur J Cancer</em> 2019;110:74-85.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ejca.2019.01.013" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30772656/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000460123000012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ACCELERATE+and+European+Medicine+Agency+Paediatric+Strategy+Forum+for+medicinal+product+development+for+mature+B-cell+malignancies+in+children.&amp;publication_year=2019&amp;journal=Eur+J+Cancer&amp;pages=74-85&amp;doi=10.1016%2Fj.ejca.2019.01.013&amp;pmid=30772656" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Ehrhardt MJ, Chen Y, Sandlund JT, et al. Late health outcomes after contemporary Lymphome Malin de Burkitt therapy for mature B-cell non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. <em>J Clin Oncol</em> 2019;37:2556-2570.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.19.00525" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31283408/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000489721100007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Late+health+outcomes+after+contemporary+Lymphome+Malin+de+Burkitt+therapy+for+mature+B-cell+non-Hodgkin+lymphoma%3A+a+report+from+the+Childhood+Cancer+Survivor+Study.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=2556-2570&amp;doi=10.1200%2FJCO.19.00525&amp;pmid=31283408" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/382/23"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">382</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">23</span></span> • <span property="datePublished">June 4, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">2207</span>-<span property="pageEnd">2219</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa1915315" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa1915315?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: June 3, 2020</div><div><b class="core-label">Published in issue</b>: June 4, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/childhood-cancer" alt="View article keyword Childhood Cancer" data-interactiontype="article_recirculation_click">Childhood Cancer</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/leukemia-lymphoma" alt="View article keyword Leukemia/Lymphoma" data-interactiontype="article_recirculation_click">Leukemia/Lymphoma</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/treatments-in-oncology" alt="View article keyword Treatments in Oncology" data-interactiontype="article_recirculation_click">Treatments in Oncology</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Véronique</span> <span property="familyName">Minard-Colin</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-0296-5207" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-0296-5207</a></span>, <span property="author" typeof="Person"><span property="givenName">Anne</span> <span property="familyName">Aupérin</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Marta</span> <span property="familyName">Pillon</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">G.A. Amos</span> <span property="familyName">Burke</span>, <span property="honorificSuffix">M.B., Ch.B., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Donald A.</span> <span property="familyName">Barkauskas</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Keith</span> <span property="familyName">Wheatley</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Rafael F.</span> <span property="familyName">Delgado</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sarah</span> <span property="familyName">Alexander</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Anne</span> <span property="familyName">Uyttebroeck</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Catherine M.</span> <span property="familyName">Bollard</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">József</span> <span property="familyName">Zsiros</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Monika</span> <span property="familyName">Csoka</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Bernarda</span> <span property="familyName">Kazanowska</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Alan K.</span> <span property="familyName">Chiang</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-1089-5325" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-1089-5325</a></span>, <span property="author" typeof="Person"><span property="givenName">Rodney R.</span> <span property="familyName">Miles</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Andrew</span> <span property="familyName">Wotherspoon</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Peter C.</span> <span property="familyName">Adamson</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Gilles</span> <span property="familyName">Vassal</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Catherine</span> <span property="familyName">Patte</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Thomas G.</span> <span property="familyName">Gross</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, for <span property="author" typeof="Person">the European Intergroup for Childhood Non-Hodgkin Lymphoma</span>, for <span property="author" typeof="Person">the Children’s Oncology Group<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Departments of Pediatric and Adolescent Oncology (V.M.-C., C.P.) and Clinical Research (G.V.), INSERM Unité 1015 (V.M.-C.), and the Unit of Biostatistics and Epidemiology and INSERM Unité 1018 (A.A.), Gustave Roussy, Université Paris-Saclay, Villejuif, France; the Department of Pediatric Hematology and Oncology, University of Padua, Padua, Italy (M.P.); the Department of Paediatric Haematology, Oncology, and Palliative Care, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Cambridge (G.A.A.B.), Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham (K.W.), and the Department of Histopathology, Royal Marsden NHS Foundation Trust, London (A.W.) — all in the United Kingdom; the Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles (D.A.B.); the Department of Pediatric Hematology and Oncology, University of Valencia, Valencia, Spain (R.F.D.); the Division of Haematology–Oncology, Hospital for Sick Children, Toronto (S.A.); the Department of Pediatric Hematology and Oncology, University Hospitals Leuven, Leuven, Belgium (A.U.); the Center for Cancer and Immunology Research, Children’s National Health System and George Washington University, Washington, DC (C.M.B.); Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands (J.Z.); the Department of Pediatric Hematology and Oncology, Semmelweis University, Budapest, Hungary (M.C.); the Department of Pediatric Bone Marrow Transplantation, Oncology, and Hematology, Wroclaw Medical University, Wroclaw, Poland (B.K.); the Department of Pediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong (A.K.C.); the Department of Pathology, University of Utah, Salt Lake City (R.R.M.); Children’s Hospital of Philadelphia, Philadelphia (P.C.A.); and the National Cancer Institute, Center for Global Health, Rockville, MD (T.G.G.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Minard-Colin at Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif 94805, France, or at <a href="mailto:veronique.minard@gustaveroussy.fr">veronique.minard@gustaveroussy.fr</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A complete list of the investigators in the European Intergroup for Childhood Non-Hodgkin Lymphoma and the Children’s Oncology Group is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div><div role="doc-footnote"><div id="fn2" role="paragraph">Drs. Minard-Colin and Aupérin and Drs. Patte and Gross contributed equally to this article.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">203</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa1915315" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="0825a1dd-7175-4f75-5829-6dcad3fdde04"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=83367156" style="display:inline-block;">
                <img alt="Article has an altmetric score of 185" src="https://badges.altmetric.com/?size=320&amp;score=185&amp;types=mbtttfd1" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=83367156">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_0825a1dd-7175-4f75-5829-6dcad3fdde04" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=83367156&amp;tab=news">
          Picked up by <b>16</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=83367156&amp;tab=blogs">
          Blogged by <b>2</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=83367156&amp;tab=policy-documents">
          Referenced in <b>1</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=83367156&amp;tab=twitter">
          Posted by <b>89</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=83367156&amp;tab=facebook">
          On <b>4</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #F4006E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=83367156&amp;tab=research-highlights">
          Highlighted by <b>1</b> platforms
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>299</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d63046808d1cd3-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa1915315"> <input type="hidden" name="downloadFileName" value="csp_382_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1915315%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.382.issue-23%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="203" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Liz Morrell, </li><li class="list-inline-item cited-by__entry__author">Malale Tungu, </li><li class="list-inline-item cited-by__entry__author">Caroline Achola, </li><li class="list-inline-item cited-by__entry__author">Ismail Legason, </li><li class="list-inline-item cited-by__entry__author">Erick Magorosa, </li><li class="list-inline-item cited-by__entry__author">Priscus Mapendo, </li><li class="list-inline-item cited-by__entry__author">Leah Mnango, </li><li class="list-inline-item cited-by__entry__author">Alex Mremi, </li><li class="list-inline-item cited-by__entry__author">Heavenlight Christopher, </li><li class="list-inline-item cited-by__entry__author">Emmanuel Josephat, </li><li class="list-inline-item cited-by__entry__author">Adam Burns, </li><li class="list-inline-item cited-by__entry__author">Helene Dreau, </li><li class="list-inline-item cited-by__entry__author">Mihaela Leonte, </li><li class="list-inline-item cited-by__entry__author">Lulu Chirande, </li><li class="list-inline-item cited-by__entry__author">Salama Mahawi, </li><li class="list-inline-item cited-by__entry__author">Elifuraha Mkwizu, </li><li class="list-inline-item cited-by__entry__author">Hadija Mwamtemi, </li><li class="list-inline-item cited-by__entry__author">Godlove Sandi, </li><li class="list-inline-item cited-by__entry__author">Claire El Mouden, </li><li class="list-inline-item cited-by__entry__author">Anna Schuh, </li><li class="list-inline-item cited-by__entry__author">George Ruhago, </li><li class="list-inline-item cited-by__entry__author">Sarah Wordsworth, </li><li class="list-inline-item cited-by__entry__author">Caroline Achola, </li><li class="list-inline-item cited-by__entry__author">Pamela Atim, </li><li class="list-inline-item cited-by__entry__author">Adam Burns, </li><li class="list-inline-item cited-by__entry__author">Clara Chamba, </li><li class="list-inline-item cited-by__entry__author">Lulu Chirande, </li><li class="list-inline-item cited-by__entry__author">Faraja Chiwanga, </li><li class="list-inline-item cited-by__entry__author">Anthony Cutts, </li><li class="list-inline-item cited-by__entry__author">Helene Dreau, </li><li class="list-inline-item cited-by__entry__author">Claire El Moulden, </li><li class="list-inline-item cited-by__entry__author">Edrick M. Elias, </li><li class="list-inline-item cited-by__entry__author">Philomena Goodluck, </li><li class="list-inline-item cited-by__entry__author">Oliver Henke, </li><li class="list-inline-item cited-by__entry__author">Kieran Howard, </li><li class="list-inline-item cited-by__entry__author">Jingjing Jiang, </li><li class="list-inline-item cited-by__entry__author">Daisy Jennings, </li><li class="list-inline-item cited-by__entry__author">Emmanuel Josephat, </li><li class="list-inline-item cited-by__entry__author">Atukuzwe Kahakwa, </li><li class="list-inline-item cited-by__entry__author">Hadija Kaliisa, </li><li class="list-inline-item cited-by__entry__author">Jacqueline Kamanga, </li><li class="list-inline-item cited-by__entry__author">Ismail D. Legason, </li><li class="list-inline-item cited-by__entry__author">Mihaela Leonte, </li><li class="list-inline-item cited-by__entry__author">Laura Lopez Pascua, </li><li class="list-inline-item cited-by__entry__author">Erick Marogosa, </li><li class="list-inline-item cited-by__entry__author">Salama Mahawi, </li><li class="list-inline-item cited-by__entry__author">Priscus Mapendo, </li><li class="list-inline-item cited-by__entry__author">William F. Mawalla, </li><li class="list-inline-item cited-by__entry__author">Sam M. Mbulaiteye, </li><li class="list-inline-item cited-by__entry__author">Daniel Mbwambo, </li><li class="list-inline-item cited-by__entry__author">Elifuraha Mkwizu, </li><li class="list-inline-item cited-by__entry__author">Leah Mnango, </li><li class="list-inline-item cited-by__entry__author">Liz Morrell, </li><li class="list-inline-item cited-by__entry__author">Alex Mremi, </li><li class="list-inline-item cited-by__entry__author">Hadija Mwamtemi, </li><li class="list-inline-item cited-by__entry__author">Liberata Mwita, </li><li class="list-inline-item cited-by__entry__author">Martin D. Ogwang, </li><li class="list-inline-item cited-by__entry__author">Isaac Otim, </li><li class="list-inline-item cited-by__entry__author">Kate Ridout, </li><li class="list-inline-item cited-by__entry__author">George Ruhago, </li><li class="list-inline-item cited-by__entry__author">Godlove Sandi, </li><li class="list-inline-item cited-by__entry__author">Raphael Sangeda, </li><li class="list-inline-item cited-by__entry__author">Patricia Scanlan, </li><li class="list-inline-item cited-by__entry__author">Kristin Schroeder, </li><li class="list-inline-item cited-by__entry__author">Anna Schuh, </li><li class="list-inline-item cited-by__entry__author">Rehema Shungu, </li><li class="list-inline-item cited-by__entry__author">Paul Shadrack Ntemi, </li><li class="list-inline-item cited-by__entry__author">Malale Tungu, </li><li class="list-inline-item cited-by__entry__author">Dimitris Vavoulis, </li><li class="list-inline-item cited-by__entry__author">Sarah Wordsworth, </li></ul><span class="cited-by__entry__title">Diagnosing Burkitt Lymphoma in Sub-Saharan Africa by Sequencing of Circulating Tumor DNA: A Comparative Microcosting Study, </span><span class="cited-by__entry__series-title">Value in Health Regional Issues, </span><span class="cited-by__entry__volume"><strong>48</strong>, </span><span class="cited-by__entry__page-range">(101113), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.vhri.2025.101113" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.vhri.2025.101113</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.vhri.2025.101113" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jing Nie, </li><li class="list-inline-item cited-by__entry__author">Lantian Huang, </li><li class="list-inline-item cited-by__entry__author">Yan Shen, </li><li class="list-inline-item cited-by__entry__author">Hongai Pan, </li><li class="list-inline-item cited-by__entry__author">Siwan Wang, </li><li class="list-inline-item cited-by__entry__author">Huawei Zhao, </li><li class="list-inline-item cited-by__entry__author">Peng Gao, </li><li class="list-inline-item cited-by__entry__author">Jufei Yang, </li><li class="list-inline-item cited-by__entry__author">Xiaojun Huang, </li><li class="list-inline-item cited-by__entry__author">Su Zeng, </li><li class="list-inline-item cited-by__entry__author">Jing Miao, </li></ul><span class="cited-by__entry__title">Methotrexate resistance and its regulatory mechanisms in pediatric tumors and beyond, </span><span class="cited-by__entry__series-title">Drug Resistance Updates, </span><span class="cited-by__entry__volume"><strong>81</strong>, </span><span class="cited-by__entry__page-range">(101225), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.drup.2025.101225" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.drup.2025.101225</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.drup.2025.101225" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Camille M. Powers, </li><li class="list-inline-item cited-by__entry__author">Sach Thakker, </li><li class="list-inline-item cited-by__entry__author">Nicholas Gulati, </li><li class="list-inline-item cited-by__entry__author">Jordan Talia, </li><li class="list-inline-item cited-by__entry__author">Danielle Dubin, </li><li class="list-inline-item cited-by__entry__author">John Zone, </li><li class="list-inline-item cited-by__entry__author">Donna A. Culton, </li><li class="list-inline-item cited-by__entry__author">Zachary Hopkins, </li><li class="list-inline-item cited-by__entry__author">Jonas A. Adalsteinsson, </li></ul><span class="cited-by__entry__title">Bullous pemphigoid: A practical approach to diagnosis and management in the modern era, </span><span class="cited-by__entry__series-title">Journal of the American Academy of Dermatology, </span><span class="cited-by__entry__volume"><strong>92</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(1337-1350), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jaad.2025.01.086" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jaad.2025.01.086</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jaad.2025.01.086" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Dequan Liu, </li><li class="list-inline-item cited-by__entry__author">Lei Liu, </li><li class="list-inline-item cited-by__entry__author">Xinming Zhao, </li><li class="list-inline-item cited-by__entry__author">Xiaoman Zhang, </li><li class="list-inline-item cited-by__entry__author">Xiaochi Chen, </li><li class="list-inline-item cited-by__entry__author">Xiangyu Che, </li><li class="list-inline-item cited-by__entry__author">Guangzhen Wu, </li></ul><span class="cited-by__entry__title">A comprehensive review on targeting diverse immune cells for anticancer therapy: Beyond immune checkpoint inhibitors, </span><span class="cited-by__entry__series-title">Critical Reviews in Oncology/Hematology, </span><span class="cited-by__entry__volume"><strong>210</strong>, </span><span class="cited-by__entry__page-range">(104702), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.critrevonc.2025.104702" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.critrevonc.2025.104702</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.critrevonc.2025.104702" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">William Frank Mawalla, </li><li class="list-inline-item cited-by__entry__author">Caroline Achola, </li><li class="list-inline-item cited-by__entry__author">Hadijah Nabalende, </li><li class="list-inline-item cited-by__entry__author">Isaac Otim, </li><li class="list-inline-item cited-by__entry__author">Ismail D. Legason, </li><li class="list-inline-item cited-by__entry__author">Martin D. Ogwang, </li><li class="list-inline-item cited-by__entry__author">Pamella M. Aol, </li><li class="list-inline-item cited-by__entry__author">Godlove Sandi, </li><li class="list-inline-item cited-by__entry__author">Hadija Mwamtemi, </li><li class="list-inline-item cited-by__entry__author">Salama Mahawi, </li><li class="list-inline-item cited-by__entry__author">Elifuraha Mkwizu, </li><li class="list-inline-item cited-by__entry__author">Philomena G. Lyamuya, </li><li class="list-inline-item cited-by__entry__author">Jacqueline P. Kamanga, </li><li class="list-inline-item cited-by__entry__author">Kristin Schroeder, </li><li class="list-inline-item cited-by__entry__author">Paul Ntemi, </li><li class="list-inline-item cited-by__entry__author">Clara Chamba, </li><li class="list-inline-item cited-by__entry__author">Dimitris Vavoulis, </li><li class="list-inline-item cited-by__entry__author">Liz Morrell, </li><li class="list-inline-item cited-by__entry__author">Lulu Chirande, </li><li class="list-inline-item cited-by__entry__author">Anna Schuh, </li></ul><span class="cited-by__entry__title">Rituximab for children with EBV-positive Burkitt lymphoma in East Africa, </span><span class="cited-by__entry__series-title">Blood Advances, </span><span class="cited-by__entry__volume"><strong>9</strong>, </span><span class="cited-by__entry__issue">10, </span><span class="cited-by__entry__page-range">(2393-2401), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1182/bloodadvances.2024015234" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1182/bloodadvances.2024015234</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1182/bloodadvances.2024015234" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Adrienne H. Long, </li><li class="list-inline-item cited-by__entry__author">Catherine Aftandilian, </li><li class="list-inline-item cited-by__entry__author">Sara Barmettler, </li><li class="list-inline-item cited-by__entry__author">Sarah Alexander, </li></ul><span class="cited-by__entry__title">Hypogammaglobulinemia in Children Receiving Targeted Immunotherapies for B Lineage Malignancies: Practical Guidance for Assessment and Management, </span><span class="cited-by__entry__series-title">Pediatric Blood &amp; Cancer, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1002/pbc.31779" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1002/pbc.31779</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1002/pbc.31779" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Evelyn Ruoyun Lu, </li><li class="list-inline-item cited-by__entry__author">Wai Lan Yeung, </li><li class="list-inline-item cited-by__entry__author">Jeffrey Ping Wa Yau, </li><li class="list-inline-item cited-by__entry__author">King Sun Chu, </li><li class="list-inline-item cited-by__entry__author">Elaine Yee Ling Kan, </li><li class="list-inline-item cited-by__entry__author">Alan Kwok Shing Chiang, </li></ul><span class="cited-by__entry__title">Case Report: Neurolymphomatosis of the peripheral nerve as a presentation of relapsed pediatric high-grade B cell lymphoma, </span><span class="cited-by__entry__series-title">Frontiers in Oncology, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fonc.2025.1477848" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fonc.2025.1477848</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fonc.2025.1477848" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ali H. Algiraigri, </li></ul><span class="cited-by__entry__title">Optimizing Outcomes in Childhood Mature B-Cell Non-Hodgkin Lymphoma: Insights Into Staging, Risk Stratification, and Response Evaluation, </span><span class="cited-by__entry__series-title">Journal of Pediatric Hematology/Oncology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1097/MPH.0000000000003046" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1097/MPH.0000000000003046</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1097/MPH.0000000000003046" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Mengsi Hu, </li><li class="list-inline-item cited-by__entry__author">Tingwei Zhang, </li><li class="list-inline-item cited-by__entry__author">Bing Liu, </li><li class="list-inline-item cited-by__entry__author">Qi Guo, </li><li class="list-inline-item cited-by__entry__author">Bing Zhao, </li><li class="list-inline-item cited-by__entry__author">Jiangong Lin, </li><li class="list-inline-item cited-by__entry__author">Zhimei Lv, </li><li class="list-inline-item cited-by__entry__author">Rong Wang, </li></ul><span class="cited-by__entry__title">Association of rituximab use with adverse events in adults with lymphoma or autoimmune disease: a single center experience, </span><span class="cited-by__entry__series-title">Frontiers in Medicine, </span><span class="cited-by__entry__volume"><strong>12</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fmed.2025.1567886" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fmed.2025.1567886</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fmed.2025.1567886" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Alon Abramovich, </li><li class="list-inline-item cited-by__entry__author">Etai Adam, </li><li class="list-inline-item cited-by__entry__author">Adi Shapira, </li><li class="list-inline-item cited-by__entry__author">Daphna Hutt, </li><li class="list-inline-item cited-by__entry__author">Orit Itzhaki, </li><li class="list-inline-item cited-by__entry__author">Bella Bielorai, </li><li class="list-inline-item cited-by__entry__author">Amos Toren, </li><li class="list-inline-item cited-by__entry__author">Elad Jacoby, </li></ul><span class="cited-by__entry__title">CD28-costimulated CD19 CAR-T cells for pediatric mature non-Hodgkin B-cell lymphoma, </span><span class="cited-by__entry__series-title">Bone Marrow Transplantation, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41409-025-02615-0" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41409-025-02615-0</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41409-025-02615-0" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1915315%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.382.issue-23%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1915315" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1915315" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1915315.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915315_f1.jpg"><img src="/cms/10.1056/NEJMoa1915315/asset/2b0f3dff-a893-4615-a023-46366d995877/assets/images/large/nejmoa1915315_f1.jpg" height="2895" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Randomization, Treatment, and Follow-up of the Patients.</div><div class="notes"><div role="doc-footnote">The 33 patients who were still receiving induction or consolidation chemotherapy after the closure of randomization in November 2015 were recommended to receive rituximab and chemotherapy regardless of the randomly assigned group; these patients were not included in the main analyses. ALL denotes acute lymphoblastic leukemia, LDH lactate dehydrogenase, PMBL primary mediastinal B-cell lymphoma, and ULN upper limit of the normal range.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915315_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915315_f2.jpg"><img src="/cms/10.1056/NEJMoa1915315/asset/edb14894-f7ee-4ade-81ca-350b1fa1cde6/assets/images/large/nejmoa1915315_f2.jpg" height="3058" width="2231" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Event-free Survival and Overall Survival, According to Treatment Group.</div><div class="notes"><div role="doc-footnote">Shown are Kaplan–Meier estimates of event-free survival (i.e., freedom from primary refractory disease or first occurrence of progression, relapse after response, death from any cause, or second cancer) and of overall survival. Vertical bars represent the Rothman 95% confidence intervals; point estimates of 36-month event-free survival and overall survival with 95% confidence intervals are shown.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915315_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915315_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1915315/asset/da3a8dc0-e43b-4b52-84d7-f0e8f26c5050/assets/images/large/nejmoa1915315_t1.jpg" height="2825" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Chemotherapy Group<br>(N=164)</th><th class="txxr-borders">Rituximab–Chemotherapy Group<br>(N=164)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders shading">137 (83.5)</td><td class="xxxr-borders shading">135 (82.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Age</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Mean — yr</td><td class="xxxx-borders shading">8.6±4.4</td><td class="xxxr-borders shading">9.2±4.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Range — yr</td><td class="xxxx-borders">2–17</td><td class="xxxr-borders">2–17</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Distribution — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">&lt;6 yr</td><td class="xxxx-borders">56 (34.1)</td><td class="xxxr-borders">44 (26.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">6 to &lt;12 yr</td><td class="xxxx-borders shading">67 (40.9)</td><td class="xxxr-borders shading">73 (44.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">12 to &lt;15 yr</td><td class="xxxx-borders">22 (13.4)</td><td class="xxxr-borders">30 (18.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">≥15 yr</td><td class="xxxx-borders shading">19 (11.6)</td><td class="xxxr-borders shading">17 (10.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Pathological diagnosis<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Burkitt’s lymphoma</td><td class="xxxx-borders shading">142 (86.6)</td><td class="xxxr-borders shading">139 (84.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Diffuse large B-cell lymphoma</td><td class="xxxx-borders">12 (7.3)</td><td class="xxxr-borders">19 (11.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">High-grade B-cell lymphoma, not otherwise specified</td><td class="xxxx-borders shading">7 (4.3)</td><td class="xxxr-borders shading">6 (3.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Primary mediastinal B-cell lymphoma<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">2 (1.2)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Precursor B-cell acute lymphoblastic leukemia<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">1 (0.6)</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Prognosis group</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Group B, low risk<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">1 (0.6)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Group B, high risk</td><td class="xxxx-borders">82 (50.0)</td><td class="xxxr-borders">81 (49.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Group C1, without CSF blasts</td><td class="xxxx-borders shading">63 (38.4)</td><td class="xxxr-borders shading">65 (39.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Group C3, with CSF blasts</td><td class="xxxx-borders">16 (9.8)</td><td class="xxxr-borders">18 (11.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Primary mediastinal B-cell lymphoma<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">2 (1.2)</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Murphy stage</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Stage III</td><td class="xxxx-borders shading">73 (44.5)</td><td class="xxxr-borders shading">70 (42.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Stage IV</td><td class="xxxx-borders">32 (19.5)</td><td class="xxxr-borders">32 (19.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Leukemic disease, mature B-cell acute leukemia</td><td class="xxxx-borders shading">57 (34.8)</td><td class="xxxr-borders shading">62 (37.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Primary mediastinal B-cell lymphoma<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">2 (1.2)</td><td class="xxxr-borders">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Central nervous system involvement</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">No</td><td class="xxxx-borders">120 (73.2)</td><td class="xxxr-borders">119 (72.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Yes</td><td class="xxxx-borders shading">44 (26.8)</td><td class="xxxr-borders shading">45 (27.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Lactate dehydrogenase</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">≤2× ULN</td><td class="xxxx-borders shading">18 (11.0)</td><td class="xxxr-borders shading">17 (10.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">&gt;2× ULN</td><td class="xxxx-borders">146 (89.0)</td><td class="xxxr-borders">147 (89.6)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Primary site or type</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Thorax</td><td class="xxxx-borders">6 (3.7)</td><td class="xxxr-borders">6 (3.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Abdomen or retroperitoneum</td><td class="xxxx-borders shading">95 (57.9)</td><td class="xxxr-borders shading">96 (58.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Head and neck, except skin and nodes</td><td class="xxxx-borders">9 (5.5)</td><td class="xxxr-borders">20 (12.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Peripheral lymph node</td><td class="xxxx-borders shading">6 (3.7)</td><td class="xxxr-borders shading">2 (1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Cerebral lymphoma</td><td class="xxxx-borders">3 (1.8)</td><td class="xxxr-borders">2 (1.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Other tumor site</td><td class="xxxx-borders shading">11 (6.7)</td><td class="xxxr-borders shading">8 (4.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13" data-xml-align="left">Clinical presentation of leukemia disease</td><td class="xbxx-borders">34 (20.7)</td><td class="xbxr-borders">30 (18.3)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Percentages may not total 100 because of rounding. CSF denotes cerebrospinal fluid, and ULN upper limit of the normal range (according to institutional values).</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">These data were obtained from national pathological review in 235 patients (72%) or from local pathological diagnosis.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Patients with these conditions were not eligible for the trial. On central review, these patients were found to be ineligible, but they were included in the intention-to-treat analyses.</div></div></div></figcaption></a><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915315_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915315_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1915315/asset/7e4ac3e3-f671-49da-854a-317570088b76/assets/images/large/nejmoa1915315_t2.jpg" height="2733" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="xxxx-borders" data-xml-align="left">Variable</th><th class="xxxx-borders" colspan="3"><span>Chemotherapy Group</span></th><th class="xxxx-borders" colspan="3"><span>Rituximab–Chemotherapy Group</span></th></tr><tr class="head2" data-type="row head2"><td class="xxxx-borders">&nbsp;</td><th class="xxxx-borders">No. of<br>Patients</th><th class="xxxx-borders">No. of Patients<br>with Event</th><th class="xxxx-borders">No. of<br>Deaths</th><th class="xxxx-borders">No. of<br>Patients</th><th class="xxxx-borders">No. of Patients<br>with Event</th><th class="xxxx-borders">No. of<br>Deaths</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02 shading" data-xml-align="left">All patients</td><td class="xxxx-borders shading">164</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">164</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Death from toxic event</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">3</td><td class="xxxx-borders">3</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">3</td><td class="xxxx-borders">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Primary refractory disease, with viable cells after CYVE2 therapy</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Relapse or progression</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">23</td><td class="xxxx-borders">15</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">3</td><td class="xxxx-borders">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Second cancer</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Total no. of events</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">28</td><td class="xxxx-borders">—</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">10</td><td class="xxxx-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Total no. of deaths</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">20</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02" data-xml-align="left">Group B</td><td class="xxxx-borders">84<a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">81</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Death from toxic event</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">2<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Primary refractory disease, with viable cells after CYVE2 therapy</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1</td><td class="xxxx-borders">1</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Relapse or progression</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">11</td><td class="xxxx-borders shading">6</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">3</td><td class="xxxx-borders shading">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Second cancer</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Total no. of events</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">14</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">5</td><td class="xxxx-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Total no. of deaths</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">—</td><td class="xxxx-borders">9</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">—</td><td class="xxxx-borders">3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02 shading" data-xml-align="left">Group C1</td><td class="xxxx-borders shading">64<a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">65</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Death from toxic event</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1</td><td class="xxxx-borders">1</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">3</td><td class="xxxx-borders">3<a href="#core-t2fn6" role="doc-noteref">‖</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Primary refractory disease, with viable cells after CYVE2 therapy</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Relapse or progression</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">8</td><td class="xxxx-borders">5</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Second cancer</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Total no. of events</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">10</td><td class="xxxx-borders">—</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">4</td><td class="xxxx-borders">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Total no. of deaths</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">7</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging02" data-xml-align="left">Group C3</td><td class="xxxx-borders">16</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">18</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Death from toxic event</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Primary refractory disease, with viable cells after CYVE2 therapy</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Relapse or progression</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">4</td><td class="xxxx-borders shading">4</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Second cancer</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">1</td><td class="xxxx-borders">1<a href="#core-t2fn7" role="doc-noteref">**</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12 shading" data-xml-align="left">Total no. of events</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">4</td><td class="xxxx-borders shading">—</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">—</td></tr><tr data-xml-align="center" data-type="row"><td class="xxxx-borders hanging12" data-xml-align="left">Total no. of deaths</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">—</td><td class="xxxx-borders">4</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">—</td><td class="xxxx-borders">1</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">CYVE2 denotes the second course of continuous infusion and high-dose cytarabine and etoposide.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">One patient in the low-risk group B (who did not have an event) was counted in group B.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">One patient who was receiving group C1 chemotherapy died after receipt of the first course of therapy with cyclophosphamide, vincristine, prednisone, doxorubicin, and methotrexate.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">One patient, a 14-year-old girl, received a diagnosis of melanoma that had developed on a congenital skin nevus 5 months after the diagnosis of Burkitt’s lymphoma.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">One patient with primary mediastinal B-cell lymphoma (who did not have an event) was counted in group B, and one (who had disease progression) was counted in group C1.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t2fn6" role="paragraph" data-to-manipulate="true">One patient switched to group C3 after receipt of the COP regimen; the death occurred after receipt of the second course of group C3 chemotherapy (cyclophosphamide, vincristine, prednisone, doxorubicin, and methotrexate).</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t2fn7" role="paragraph" data-to-manipulate="true">One patient, a 6-year-old boy, had fatal histiocytic sarcoma with an identical t(8;14) <i>IGH</i>–<i>MYC</i> anomaly, which had been diagnosed when he was 16.6 months of age.</div></div></div></figcaption></a><figcaption><div class="caption">Number and Type of Events and Number of Deaths.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915315_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915315_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1915315/asset/aa2899de-a4c3-4a9d-9be4-182744a20023/assets/images/large/nejmoa1915315_t3.jpg" height="2668" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders">All Patients<br>(N=315)</th><th class="txxx-borders">Chemotherapy Group<br>(N=153)</th><th class="txxx-borders">Rituximab–Chemotherapy Group<br>(N=162)</th><th class="txxr-borders">P Value</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="3"><span>no. of patients (%)</span></th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading"><b>During all therapy</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">≥1 Adverse event</td><td class="xxxx-borders">306 (97.1)</td><td class="xxxx-borders">148 (96.7)</td><td class="xxxx-borders">158 (97.5)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">≥1 Adverse event of grade ≥4</td><td class="xxxx-borders shading">111 (35.2)</td><td class="xxxx-borders shading">50 (32.7)</td><td class="xxxx-borders shading">61 (37.7)</td><td class="xxxr-borders shading">0.36</td></tr><tr data-type="row"><td class="xxlx-borders hanging03"><b>During COP prephase treatment</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">≥1 Adverse event</td><td class="xxxx-borders shading">63 (20.0)</td><td class="xxxx-borders shading">31 (20.3)</td><td class="xxxx-borders shading">32 (19.8)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">≥1 Adverse event of grade ≥4</td><td class="xxxx-borders">27 (8.6)</td><td class="xxxx-borders">17 (11.1)</td><td class="xxxx-borders">10 (6.2)</td><td class="xxxr-borders">0.12</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading"><b>After COP prephase treatment</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">≥1 Adverse event</td><td class="xxxx-borders">303 (96.2)</td><td class="xxxx-borders">147 (96.1)</td><td class="xxxx-borders">156 (96.3)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">≥1 Adverse event of grade ≥4</td><td class="xxxx-borders shading">91 (28.9)</td><td class="xxxx-borders shading">37 (24.2)</td><td class="xxxx-borders shading">54 (33.3)</td><td class="xxxr-borders shading">0.07</td></tr><tr data-type="row"><td class="xxlx-borders hanging03"><b>Most frequent adverse events after COP prephase treatment</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Febrile neutropenia</td><td class="xxxx-borders shading">289 (91.7)</td><td class="xxxx-borders shading">139 (90.8)</td><td class="xxxx-borders shading">150 (92.6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Grade 3</td><td class="xxxx-borders">260 (82.5)</td><td class="xxxx-borders">129 (84.3)</td><td class="xxxx-borders">131 (80.9)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Grade ≥4</td><td class="xxxx-borders shading">29 (9.2)</td><td class="xxxx-borders shading">10 (6.5)</td><td class="xxxx-borders shading">19 (11.7)</td><td class="xxxr-borders shading">0.11</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Stomatitis</td><td class="xxxx-borders">244 (77.5)</td><td class="xxxx-borders">115 (75.2)</td><td class="xxxx-borders">129 (79.6)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Grade 3</td><td class="xxxx-borders shading">224 (71.1)</td><td class="xxxx-borders shading">108 (70.6)</td><td class="xxxx-borders shading">116 (71.6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Grade ≥4</td><td class="xxxx-borders">20 (6.3)</td><td class="xxxx-borders">7 (4.6)</td><td class="xxxx-borders">13 (8.0)</td><td class="xxxr-borders">0.21</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Enteritis</td><td class="xxxx-borders shading">63 (20.0)</td><td class="xxxx-borders shading">24 (15.7)</td><td class="xxxx-borders shading">39 (24.1)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Grade 3</td><td class="xxxx-borders">62 (19.7)</td><td class="xxxx-borders">24 (15.7)</td><td class="xxxx-borders">38 (23.5)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Grade ≥4</td><td class="xxxx-borders shading">1 (0.3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.6)</td><td class="xxxr-borders shading">1.00</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Infection</td><td class="xxxx-borders">170 (54.0)</td><td class="xxxx-borders">75 (49.0)</td><td class="xxxx-borders">95 (58.6)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Grade 3</td><td class="xxxx-borders shading">123 (39.0)</td><td class="xxxx-borders shading">58 (37.9)</td><td class="xxxx-borders shading">65 (40.1)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Grade ≥4</td><td class="xxxx-borders">47 (14.9)</td><td class="xxxx-borders">17 (11.1)</td><td class="xxxx-borders">30 (18.5)</td><td class="xxxr-borders">0.07</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Main types of infection</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Sepsis</td><td class="xxxx-borders">45 (14.3)</td><td class="xxxx-borders">17 (11.1)</td><td class="xxxx-borders">28 (17.3)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Central venous catheter– related infection</td><td class="xxxx-borders shading">38 (12.1)</td><td class="xxxx-borders shading">17 (11.1)</td><td class="xxxx-borders shading">21 (13.0)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Lung infection</td><td class="xxxx-borders">32 (10.2)</td><td class="xxxx-borders">13 (8.5)</td><td class="xxxx-borders">19 (11.7)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Enterocolitis infection</td><td class="xxxx-borders shading">32 (10.2)</td><td class="xxxx-borders shading">18 (11.8)</td><td class="xxxx-borders shading">14 (8.6)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Biologic adverse events</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Alanine aminotransferase increased</td><td class="xxxx-borders shading">41 (13.0)</td><td class="xxxx-borders shading">18 (11.8)</td><td class="xxxx-borders shading">23 (14.2)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Grade 3</td><td class="xxxx-borders">25 (7.9)</td><td class="xxxx-borders">12 (7.8)</td><td class="xxxx-borders">13 (8.0)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Grade ≥4</td><td class="xxxx-borders shading">16 (5.1)</td><td class="xxxx-borders shading">6 (3.9)</td><td class="xxxx-borders shading">10 (6.2)</td><td class="xxxr-borders shading">0.36</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Hypokalemia</td><td class="xxxx-borders">36 (11.4)</td><td class="xxxx-borders">15 (9.8)</td><td class="xxxx-borders">21 (13.0)</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Grade 3</td><td class="xxxx-borders shading">28 (8.9)</td><td class="xxxx-borders shading">11 (7.2)</td><td class="xxxx-borders shading">17 (10.5)</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging23" data-xml-align="left">Grade ≥4</td><td class="xbxx-borders">8 (2.5)</td><td class="xbxx-borders">4 (2.6)</td><td class="xbxx-borders">4 (2.5)</td><td class="xbxr-borders">1.00</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Shown are the numbers and percentages of patients who had at least one adverse event, those who had at least one adverse event of grade 4 or higher, and those who had the most frequent acute adverse events (i.e., events occurring in &gt;10% of the patients overall). A total of 13 patients who did not have data on treatment or adverse events or who received only prephase treatment (a regimen of cyclophosphamide, vincristine, and prednisone [COP]) were not included in this analysis. Only nonhematologic adverse events of grade 3 or higher or cardiac adverse events of grade 2 or higher were recorded. P values are shown for events of grade 4 or higher.</div></div></div></figcaption></a><figcaption><div class="caption">Acute Adverse Events.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1915315_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa1915315</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Minard-Colin V, Brugières L, Reiter A, et al. Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. <em>J Clin Oncol</em> 2015;33:2963-2974.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2014.59.5827" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26304908/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000366018800004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Non-Hodgkin+lymphoma+in+children+and+adolescents%3A+progress+through+effective+collaboration%2C+current+knowledge%2C+and+challenges+ahead.&amp;publication_year=2015&amp;journal=J+Clin+Oncol&amp;pages=2963-2974&amp;doi=10.1200%2FJCO.2014.59.5827&amp;pmid=26304908" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. <em>Blood</em> 2005;105:948-958.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2004-03-0973" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15486066/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000226596700016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+impact+of+the+methotrexate+administration+schedule+and+dose+in+the+treatment+of+children+and+adolescents+with+B-cell+neoplasms%3A+a+report+of+the+BFM+Group+Study+NHL-BFM95.&amp;publication_year=2005&amp;journal=Blood&amp;pages=948-958&amp;doi=10.1182%2Fblood-2004-03-0973&amp;pmid=15486066" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. <em>Blood</em> 2007;109:2773-2780.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2006-07-036673" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17132719/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000245639000025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Results+of+the+randomized+international+FAB%2FLMB96+trial+for+intermediate+risk+B-cell+non-Hodgkin+lymphoma+in+children+and+adolescents%3A+it+is+possible+to+reduce+treatment+for+the+early+responding+patients.&amp;publication_year=2007&amp;journal=Blood&amp;pages=2773-2780&amp;doi=10.1182%2Fblood-2006-07-036673&amp;pmid=17132719" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] showing survival of approximately 90%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] as a 24-hour infusion (group C3). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] Supplementary Appendix). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] the basis of data from the FAB/LMB96 study. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. <em>Blood</em> 2007;109:2736-2743.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2006-07-036665" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17138821/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000245639000020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Results+of+a+randomized+international+study+of+high-risk+central+nervous+system+B+non-Hodgkin+lymphoma+and+B+acute+lymphoblastic+leukemia+in+children+and+adolescents.&amp;publication_year=2007&amp;journal=Blood&amp;pages=2736-2743&amp;doi=10.1182%2Fblood-2006-07-036665&amp;pmid=17138821" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] showing survival of approximately 90%. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] as a 24-hour infusion (group C3). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] Supplementary Appendix). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] the basis of data from the FAB/LMB96 study. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Havelange V, Pepermans X, Ameye G, et al. Genetic differences between paediatric and adult Burkitt lymphomas. <em>Br J Haematol</em> 2016;173:137-144.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r5-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.13925" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26887776/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000373138700013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genetic+differences+between+paediatric+and+adult+Burkitt+lymphomas.&amp;publication_year=2016&amp;journal=Br+J+Haematol&amp;pages=137-144&amp;doi=10.1111%2Fbjh.13925&amp;pmid=26887776" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r5-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] prognoses and sensitivities to treatments. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] heterogeneity in Burkitt’s lymphomagenesis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">López C, Kleinheinz K, Aukema SM, et al. Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. <em>Nat Commun</em> 2019;10:1459-1459.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41467-019-08578-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30926794/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000462722700006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Genomic+and+transcriptomic+changes+complement+each+other+in+the+pathogenesis+of+sporadic+Burkitt+lymphoma.&amp;publication_year=2019&amp;journal=Nat+Commun&amp;pages=1459-1459&amp;doi=10.1038%2Fs41467-019-08578-3&amp;pmid=30926794" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] prognoses and sensitivities to treatments. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] heterogeneity in Burkitt’s lymphomagenesis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report. <em>Leukemia</em> 2013;27:1174-1177.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/leu.2012.255" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22940833/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000318698300022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rituximab+and+FAB%2FLMB+96+chemotherapy+in+children+with+stage+III%2FIV+B-cell+non-Hodgkin+lymphoma%3A+a+Children%E2%80%99s+Oncology+Group+report.&amp;publication_year=2013&amp;journal=Leukemia&amp;pages=1174-1177&amp;doi=10.1038%2Fleu.2012.255&amp;pmid=22940833" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] malins B (LMB) chemotherapy regimen. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] courses, for a total of six doses. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Minard-Colin V, Auperin A, Leverger G. In childhood B-cell non Hodgkin’s lymphoma (B-NHL) and mature B-cell acute leukemia (B-AL) with CNS disease at diagnosis, patients with blasts in CSF are at higher risk of event. <em>Ann Oncol</em> 2011;22:Suppl 4:iv112-iv114.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000291996300101" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=In+childhood+B-cell+non+Hodgkin%E2%80%99s+lymphoma+%28B-NHL%29+and+mature+B-cell+acute+leukemia+%28B-AL%29+with+CNS+disease+at+diagnosis%2C+patients+with+blasts+in+CSF+are+at+higher+risk+of+event.&amp;publication_year=2011&amp;journal=Ann+Oncol&amp;pages=iv112-iv114" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. <em>Stat Med</em> 1994;13:1341-1352.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/sim.4780131308" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7973215/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1994PA16800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Interim+analysis%3A+the+alpha+spending+function+approach.&amp;publication_year=1994&amp;journal=Stat+Med&amp;pages=1341-1352&amp;doi=10.1002%2Fsim.4780131308&amp;pmid=7973215" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Minard-Colin V, Auperin A, Pillon M, et al. Results of the randomized Intergroup trial Inter-B-NHL ritux 2010 for children and adolescents with high-risk B-cell non-Hodgkin lymphoma (B-NHL) and mature acute leukemia (B-AL): evaluation of rituximab (R) efficacy in addition to standard LMB chemotherapy (CT) regimen. <em>J Clin Oncol</em> 2016;34:Suppl:10507-10507. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2016.34.15_suppl.10507" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000404712500302" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Results+of+the+randomized+Intergroup+trial+Inter-B-NHL+ritux+2010+for+children+and+adolescents+with+high-risk+B-cell+non-Hodgkin+lymphoma+%28B-NHL%29+and+mature+acute+leukemia+%28B-AL%29%3A+evaluation+of+rituximab+%28R%29+efficacy+in+addition+to+standard+LMB+chemotherapy+%28CT%29+regimen.&amp;publication_year=2016&amp;journal=J+Clin+Oncol&amp;pages=10507-10507&amp;doi=10.1200%2FJCO.2016.34.15_suppl.10507" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, phase 3 trial. <em>Lancet</em> 2016;387:2402-2411.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(15)01317-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27080498/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000377560100033" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rituximab+and+dose-dense+chemotherapy+for+adults+with+Burkitt%E2%80%99s+lymphoma%3A+a+randomised%2C+controlled%2C+open-label%2C+phase+3+trial.&amp;publication_year=2016&amp;journal=Lancet&amp;pages=2402-2411&amp;doi=10.1016%2FS0140-6736%2815%2901317-3&amp;pmid=27080498" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Focosi D, Tuccori M, Maggi F. Progressive multifocal leukoencephalopathy and anti-CD20 monoclonal antibodies: what do we know after 20 years of rituximab. <em>Rev Med Virol</em> 2019;29(6):e2077-e2077.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/rmv.2077" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31369199/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000479823200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Progressive+multifocal+leukoencephalopathy+and+anti-CD20+monoclonal+antibodies%3A+what+do+we+know+after+20+years+of+rituximab.&amp;publication_year=2019&amp;journal=Rev+Med+Virol&amp;pages=e2077-e2077&amp;doi=10.1002%2Frmv.2077&amp;pmid=31369199" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Kusumoto S, Arcaini L, Hong X, et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. <em>Blood</em> 2019;133:137-146.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2018-04-848044" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30341058/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000455409800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+of+HBV+reactivation+in+patients+with+B-cell+lymphomas+receiving+obinutuzumab+or+rituximab+immunochemotherapy.&amp;publication_year=2019&amp;journal=Blood&amp;pages=137-146&amp;doi=10.1182%2Fblood-2018-04-848044&amp;pmid=30341058" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Tao L, Clarke CA, Rosenberg AS, et al. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. <em>Br J Haematol</em> 2017;178:72-80.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.14638" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28542862/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000404042700010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Subsequent+primary+malignancies+after+diffuse+large+B-cell+lymphoma+in+the+modern+treatment+era.&amp;publication_year=2017&amp;journal=Br+J+Haematol&amp;pages=72-80&amp;doi=10.1111%2Fbjh.14638&amp;pmid=28542862" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Fleury I, Chevret S, Pfreundschuh M, et al. Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. <em>Ann Oncol</em> 2016;27:390-397.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdv616" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26681685/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000371691600006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rituximab+and+risk+of+second+primary+malignancies+in+patients+with+non-Hodgkin+lymphoma%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2016&amp;journal=Ann+Oncol&amp;pages=390-397&amp;doi=10.1093%2Fannonc%2Fmdv616&amp;pmid=26681685" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Meinhardt A, Burkhardt B, Zimmermann M, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt leukemia. <em>J Clin Oncol</em> 2010;28:3115-3121.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2009.26.6791" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20516455/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000279254300005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+II+window+study+on+rituximab+in+newly+diagnosed+pediatric+mature+B-cell+non-Hodgkin%E2%80%99s+lymphoma+and+Burkitt+leukemia.&amp;publication_year=2010&amp;journal=J+Clin+Oncol&amp;pages=3115-3121&amp;doi=10.1200%2FJCO.2009.26.6791&amp;pmid=20516455" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Tout M, Casasnovas O, Meignan M, et al. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. <em>Blood</em> 2017;129:2616-2623.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2016-10-744292" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28251914/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000400980000008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rituximab+exposure+is+influenced+by+baseline+metabolic+tumor+volume+and+predicts+outcome+of+DLBCL+patients%3A+a+Lymphoma+Study+Association+report.&amp;publication_year=2017&amp;journal=Blood&amp;pages=2616-2623&amp;doi=10.1182%2Fblood-2016-10-744292&amp;pmid=28251914" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Barth MJ, Goldman S, Smith L, et al. Rituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children’s Oncology Group report. <em>Br J Haematol</em> 2013;162:678-683.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bjh.12434" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23802659/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000323158400012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rituximab+pharmacokinetics+in+children+and+adolescents+with+de+novo+intermediate+and+advanced+mature+B-cell+lymphoma%2Fleukaemia%3A+a+Children%E2%80%99s+Oncology+Group+report.&amp;publication_year=2013&amp;journal=Br+J+Haematol&amp;pages=678-683&amp;doi=10.1111%2Fbjh.12434&amp;pmid=23802659" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Patte C, Zimmerman M, Auperin A, Reiter A. Similar results are currently observed in the LMB and BFM studies for B-cell Non-Hodgkin’s lymphoma and B-AL allowing future common studies. <em>Pediatr Blood Cancer</em> 2010;55:795-795. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000282910200075" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Similar+results+are+currently+observed+in+the+LMB+and+BFM+studies+for+B-cell+Non-Hodgkin%E2%80%99s+lymphoma+and+B-AL+allowing+future+common+studies.&amp;publication_year=2010&amp;journal=Pediatr+Blood+Cancer&amp;pages=795-795" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Pearson ADJ, Scobie N, Norga K, et al. ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children. <em>Eur J Cancer</em> 2019;110:74-85.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ejca.2019.01.013" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30772656/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000460123000012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ACCELERATE+and+European+Medicine+Agency+Paediatric+Strategy+Forum+for+medicinal+product+development+for+mature+B-cell+malignancies+in+children.&amp;publication_year=2019&amp;journal=Eur+J+Cancer&amp;pages=74-85&amp;doi=10.1016%2Fj.ejca.2019.01.013&amp;pmid=30772656" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Ehrhardt MJ, Chen Y, Sandlund JT, et al. Late health outcomes after contemporary Lymphome Malin de Burkitt therapy for mature B-cell non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. <em>J Clin Oncol</em> 2019;37:2556-2570.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r21"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.19.00525" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31283408/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000489721100007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Late+health+outcomes+after+contemporary+Lymphome+Malin+de+Burkitt+therapy+for+mature+B-cell+non-Hodgkin+lymphoma%3A+a+report+from+the+Childhood+Cancer+Survivor+Study.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=2556-2570&amp;doi=10.1200%2FJCO.19.00525&amp;pmid=31283408" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> Manhasset, New York</span></div><div><span>Chiefs / Directors / Dept. Heads</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/878250/director-of-lung-cancer-screening-/?query=fjwp&amp;rid=3059">Director of Lung Cancer Screening </a></div></div><div class="nejm-widget_item"><div><span> Sayre, Pennsylvania</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/893291/family-medicine-residency-program-director-sayre-pa-/?query=fjwp&amp;rid=899">Family Medicine - Residency Program Director (Sayre, PA)</a></div></div><div class="nejm-widget_item"><div><span> Spanish Fork, Utah</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/881339/obgyn-physician/?query=fjwf&amp;rid=751">OBGYN Physician</a></div></div><div class="nejm-widget_item"><div><span> Brooklyn, New York</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891349/family-medicine-physician/?query=fjwf&amp;rid=12619">Family Medicine Physician</a></div></div><div class="nejm-widget_item"><div><span> Kingman, Arizona</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/888203/medical-oncologist/?query=fjwf&amp;rid=14142">Medical Oncologist</a></div></div><div class="nejm-widget_item"><div><span> Lancaster, Pennsylvania</span></div><div><span>Hospitalist</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887338/nocturnist-needed-in-prestigious-health-system-located-in-scenic-lancaster-pa/?query=fjwp&amp;rid=421419">Nocturnist Needed in Prestigious Health System Located in Scenic Lancaster, PA</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128743&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Fnotablearticles2024%3Fpromo%3DONFQNAR4%26query%3Dcm-ra%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dna24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1915315&amp;pubId=41288907&amp;placeholderId=101337&amp;productId=1007"><img src="/sda/128743/rightRail--notable24_001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d63046808d1cd3-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d63046808d1cd3-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d63046808d1cd3-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$027599221$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$027599221$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$027599221$--></div></div><div class="mlt-body"><!--?lit$027599221$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$027599221$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$027599221$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$027599221$-->Feb 15, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2313398?query=recirc_Semantic" target="_self">Brief Report: High-Dose ERT, Rituximab, and Early HSCT in an Infant with Wolman’s Disease</a></div><div class="mlt-article-authors"><!--?lit$027599221$-->S.K. Eskandari and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$027599221$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$027599221$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$027599221$-->Jun 30, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2201817?query=recirc_Semantic" target="_self">Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma</a></div><div class="mlt-article-authors"><!--?lit$027599221$-->M.L. Wang and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$027599221$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$027599221$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$027599221$-->May 13, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2031298?query=recirc_Semantic" target="_self">Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia</a></div><div class="mlt-article-authors"><!--?lit$027599221$-->E. Tiacci and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$027599221$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$027599221$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$027599221$-->Jun 17, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2028564?query=recirc_Semantic" target="_self">Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris</a></div><div class="mlt-article-authors"><!--?lit$027599221$-->V.P. Werth and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$027599221$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$027599221$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$027599221$-->Jul 25, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2312948?query=recirc_Semantic" target="_self">Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults</a></div><div class="mlt-article-authors"><!--?lit$027599221$-->M.R. Litzow and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa1915315?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa1915315" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1915315.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa1915315"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2003892" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMsa1916744" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Handgun Ownership and Suicide in California</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915315_f1.jpg"><img src="/cms/10.1056/NEJMoa1915315/asset/2b0f3dff-a893-4615-a023-46366d995877/assets/images/large/nejmoa1915315_f1.jpg" height="2895" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Randomization, Treatment, and Follow-up of the Patients.</div><div class="notes"><div role="doc-footnote">The 33 patients who were still receiving induction or consolidation chemotherapy after the closure of randomization in November 2015 were recommended to receive rituximab and chemotherapy regardless of the randomly assigned group; these patients were not included in the main analyses. ALL denotes acute lymphoblastic leukemia, LDH lactate dehydrogenase, PMBL primary mediastinal B-cell lymphoma, and ULN upper limit of the normal range.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1915315_f2.jpg"><img src="/cms/10.1056/NEJMoa1915315/asset/edb14894-f7ee-4ade-81ca-350b1fa1cde6/assets/images/large/nejmoa1915315_f2.jpg" height="3058" width="2231" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Event-free Survival and Overall Survival, According to Treatment Group.</div><div class="notes"><div role="doc-footnote">Shown are Kaplan–Meier estimates of event-free survival (i.e., freedom from primary refractory disease or first occurrence of progression, relapse after response, death from any cause, or second cancer) and of overall survival. Vertical bars represent the Rothman 95% confidence intervals; point estimates of 36-month event-free survival and overall survival with 95% confidence intervals are shown.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Characteristics of the Patients at Baseline.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Number and Type of Events and Number of Deaths.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Acute Adverse Events.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/382/23" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 382 No. 23</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 04, 2020</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2003892" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">C.N. Sternberg and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 04, 2020</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2004325" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">N.D. Shore and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/clinical-practice" class="issue-item_type">Clinical Practice</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 04, 2020</span></li><li data-toggle="tooltip" data-original-title="Audio" class="issue-item_meta-item"><span role="img" aria-label="Audio" tabindex="0" class="issue-item_audio"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-audio"></use></svg></span></span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMcp1905840" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Bedbugs</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">P. Parola and A. Izri</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1915315%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1915315&amp;pubId=41288907&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1915315%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1915315&amp;pubId=41288907&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id0779076900976592" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d63046808d1cd3-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d63046808d1cd3-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d63046808d1cd3-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d63046808d1cd3-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d63046808d1cd3-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d63046808d1cd3-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d63046808d1cd3-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d63046808d1cd3-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d63046808d1cd3-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d63046808d1cd3-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d630467a021cd3',t:'MTc0OTUzMDQwNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d630467a021cd3&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa1915315?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=1-10"></script><iframe name="captureIFrame_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" data-transactionid="9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" id="captureIFrame_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" target="captureIFrame_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" name="capture_screen"><input id="capture_signIn_js_version_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" name="js_version"><input id="capture_signIn_transactionId_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" data-capturefield="undefined" value="9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" type="hidden" class="capture_transactionId_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" name="capture_transactionId"><input id="capture_signIn_form_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" name="form"><input id="capture_signIn_flow_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" name="flow"><input id="capture_signIn_client_id_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" name="client_id"><input id="capture_signIn_redirect_uri_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" name="redirect_uri"><input id="capture_signIn_response_type_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" name="response_type"><input id="capture_signIn_flow_version_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" name="flow_version"><input id="capture_signIn_settings_version_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" name="settings_version"><input id="capture_signIn_locale_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" name="locale"><input id="capture_signIn_recaptcha_version_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_9n6a519hwarv424z7sf8qo434g14byorjmyje3fa" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><tcu-nzqxlixemqvp></tcu-nzqxlixemqvp><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div></body></html>